# Non-small-cell lung cancer

Source: https://onco.cc/cancers/nsclc/  
OnCo record `nsclc` (Cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story.

## Summary

Non-small-cell lung cancer is ~85% of lung cancer and the cancer where precision medicine has gone furthest. Adenocarcinoma (~50%) and squamous cell carcinoma (~25-30%) dominate; large-cell and other histologies make up the rest. Roughly half of adenocarcinomas carry a targetable driver (EGFR ~15% Western/40-50% East Asian, KRAS ~30% Western, ALK ~5%, MET ex14 ~3%, HER2 ~2-3%, BRAF V600E ~2%, RET ~1-2%, ROS1 ~1-2%, NTRK <1%), which makes broad genomic profiling at diagnosis mandatory. Tobacco drives most squamous and KRAS-mutant disease; never-smoker adenocarcinoma, increasingly common in East Asian women, is EGFR- and ALK-enriched. Lung cancer as a whole remains the leading cause of cancer death worldwide (~1.8 million deaths a year), largely because most cases are still found late.

Care is organised by stage and driver. Low-dose CT screening (NLST, NELSON) cuts mortality but is under-used. Early-stage disease is resected (lobectomy or, for small peripheral tumours, segmentectomy) or ablated with SBRT; perioperative immunotherapy (CheckMate 816, KEYNOTE-671) and adjuvant targeted therapy (ADAURA for EGFR, ALINA for ALK) are standard. Stage III unresectable disease gets chemoradiation followed by durvalumab (PACIFIC) or osimertinib if EGFR-mutant (LAURA). Metastatic driver-positive disease receives a matched TKI or bispecific first (osimertinib or amivantamab-lazertinib; lorlatinib or alectinib; repotrectinib or zidesamtinib; sotorasib or adagrasib after chemo-IO; selpercatinib; capmatinib or tepotinib; zongertinib or sevabertinib; dabrafenib-trametinib), then chemotherapy and ADCs (Dato-DXd approved 2025 in EGFR-mutant disease). Driver-negative metastatic disease gets PD-(L)1 blockade with or without platinum doublets depending on PD-L1 TPS, with tremelimumab-durvalumab-chemotherapy for PD-L1-negative and STK11/KEAP1-altered tumours.

The frontier is fourfold: (1) beating osimertinib and pembrolizumab head-to-head (MARIPOSA succeeded; HARMONi-2 succeeded in China while HARMONi-3 missed its interim PFS analysis in May 2026, with an FDA decision on ivonescimab due 14 November 2026); (2) next-generation TKIs that clear compound resistance (neladalkib PDUFA 27 November 2026; divarasib superior to first-generation KRAS inhibitors in Krascendo 1); (3) ADCs and bispecific ADCs after TKI failure, tempered by HERTHENA-Lung02's failure to improve survival and TROPION-Lung01's mixed result; and (4) earlier intervention via MRD-guided adjuvant therapy, neoadjuvant targeted therapy (NeoADAURA), and AI-assisted screening.

## Fields

- Kind: Cancer
- Last checked: 2026-09-06
- Also known as: LUAD; LUSC; LSCC; TCGA-LUAD; TCGA-LUSC; lung adenocarcinoma (TCGA LUAD cohort); lung squamous cell carcinoma (TCGA LUSC and CPTAC LSCC cohorts)
- Tags: lung; spike
- Group: lung
- Burden: ~85% of lung cancer. Low-dose CT screening catches cancers in people at high risk while they are still curable (NLST, NELSON), and a dozen targetable drivers each have a matched drug. Lung cancer still accounts for about 1.8 million deaths a year worldwide, more than any other cancer, largely because most cases are found late.
- Subtypes: Adenocarcinoma; Squamous; EGFR-mutant; ALK-rearranged; KRAS-mutant; PD-L1-high; Adenocarcinoma (~50%); Squamous cell carcinoma (~25-30%); Large-cell / NOS; EGFR-mutant (exon 19 del, L858R, exon 20 ins, uncommon); ROS1-rearranged; KRAS G12C and non-G12C; BRAF V600E; MET exon 14 skipping / MET-amplified; RET-fusion; HER2-mutant; NTRK-fusion; Driver-negative PD-L1-high (TPS ≥50%); Driver-negative PD-L1-low/negative; STK11/KEAP1 co-mutated (IO-resistant)
- Biomarkers: EGFR; ALK; ROS1; BRAF V600E; MET ex14 / amplification / c-MET IHC; RET; NTRK; KRAS G12C; HER2 mutation; PD-L1 TPS; ctDNA; PD-L1 TPS (22C3); EGFR (exon 19 del, L858R, exon 20 ins, T790M, C797S); ALK fusion; ROS1 fusion; KRAS G12C (and G12D/V); MET exon 14 skipping, MET amplification, c-Met IHC; RET fusion; HER2 (ERBB2) mutation; NTRK fusion; STK11 / KEAP1 (prognostic, IO resistance); TP53 / RB1 (transformation risk); ctDNA (genotyping, MRD, resistance tracking); TMB (limited use)

## Sections of this record

The page is a hub with ten sections in reading order; large sections have their own page. The same plan as JSON: https://onco.cc/api/v1/cancers/nsclc/sections.json

- Overview (on the hub): The TL;DR, the family this cancer belongs to, the organ, who gets it and what the state of the art is. https://onco.cc/cancers/nsclc/#overview [22 subtypes, 10 state-of-the-art points]
- What it is (own page): Anatomy, the subtypes and how they differ, how it is staged, and where advanced disease spreads. https://onco.cc/cancers/nsclc/what-it-is/ [42 subtypes, 6 sites of spread]
- Finding it (own page): How it shows itself, how it is confirmed, what screening exists, and the biomarkers clinicians test for. https://onco.cc/cancers/nsclc/finding-it/ [24 biomarkers, 21 prevalence rows]
- Treating it (on the hub): The standard of care by setting, the medicines, surgery and radiotherapy named in it, and the regimens behind them. https://onco.cc/cancers/nsclc/#treating-it [21 settings, 12 regimens, 19 decisions with options]
- Evidence (own page): Trials recruiting now, the landmark trials, the key papers and what they mean, the latest literature, and the milestones year by year. https://onco.cc/cancers/nsclc/evidence/ [592 trials, 46 key papers, 20 milestones]
- The science (own page): The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models. https://onco.cc/cancers/nsclc/science/ [179 targets, 13 pathways, 14 preclinical models]
- Where you are (own page): Cases by country, the UK and NHS pathway and other country lenses, and the expert centres with trials on record. https://onco.cc/cancers/nsclc/where-you-are/ [81 centres]
- Living with it (own page): The decisions you may face, the aids that walk through them, the warnings on record, the first sixty days and the questions to ask. https://onco.cc/cancers/nsclc/living-with-it/ [61 questions, 6 red cards]
- What is coming (own page): Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record. https://onco.cc/cancers/nsclc/coming/ [219 medicines, 592 trials, 84 ideas, 11 open problems]
- Data (own page): Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked. https://onco.cc/cancers/nsclc/data/ [1735 connected records]

## Standard of care

- Screening: Annual low-dose CT for high-risk smokers (NLST, NELSON); AI nodule scoring emerging. ([CT (computed tomography)](https://onco.cc/technologies/ct/), [AI in radiology](https://onco.cc/technologies/radiology-ai-screening/))
- Early stage: Surgery or SBRT; perioperative chemo-immunotherapy; adjuvant osimertinib (EGFR) or alectinib (ALK). ([SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/), [ADAURA](https://onco.cc/trials/adaura/), [Osimertinib](https://onco.cc/drugs/osimertinib/))
- Stage III unresectable: Chemoradiation → durvalumab (PACIFIC) or osimertinib (LAURA, EGFR). ([Durvalumab](https://onco.cc/drugs/durvalumab/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/))
- Metastatic, driver-positive: Matched TKI or bispecific; ADCs after progression. ([Osimertinib](https://onco.cc/drugs/osimertinib/), [Amivantamab](https://onco.cc/drugs/amivantamab/), [Lorlatinib](https://onco.cc/drugs/lorlatinib/), [Selpercatinib](https://onco.cc/drugs/selpercatinib/), [Zongertinib](https://onco.cc/drugs/zongertinib/), [Sotorasib](https://onco.cc/drugs/sotorasib/), [Datopotamab deruxtecan](https://onco.cc/drugs/datopotamab-deruxtecan/))
- Metastatic, driver-negative: PD-(L)1 ± chemotherapy; docetaxel or ADC/TTFields second line. ([Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Optune / Optune Pax (TTFields)](https://onco.cc/drugs/optune/))
- Screening (age 50-80, ≥20 pack-years): Annual low-dose CT with Lung-RADS reporting; AI nodule scoring emerging; robotic bronchoscopy for peripheral nodule biopsy. ([Low-dose CT lung screening](https://onco.cc/technologies/low-dose-ct-screening/), [NLST & NELSON (low-dose CT screening)](https://onco.cc/trials/nlst-nelson/), [Robotic and navigational bronchoscopy](https://onco.cc/technologies/robotic-bronchoscopy/), [AI in radiology](https://onco.cc/technologies/radiology-ai-screening/))
- Stage I-II resectable: Lobectomy or segmentectomy (small peripheral) with nodal staging; SBRT if inoperable. Stage IB-IIIA: neoadjuvant chemo-IO (CheckMate 816) or perioperative chemo-IO (KEYNOTE-671); adjuvant osimertinib if EGFR-mutant (ADAURA), alectinib if ALK-positive (ALINA); adjuvant chemotherapy otherwise for stage II+. ([Robotic & minimally invasive surgery](https://onco.cc/technologies/robotic-surgery/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/), [CheckMate 816](https://onco.cc/trials/checkmate-816/), [KEYNOTE-671](https://onco.cc/trials/keynote-671/), [ADAURA](https://onco.cc/trials/adaura/), [ALINA](https://onco.cc/trials/alina/), [Osimertinib](https://onco.cc/drugs/osimertinib/), [Alectinib](https://onco.cc/drugs/alectinib/))
- Stage III unresectable: Concurrent platinum chemoradiation → durvalumab 1 year (PACIFIC), or osimertinib until progression if EGFR-mutant (LAURA). Proton therapy in selected cases. ([IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [PACIFIC](https://onco.cc/trials/pacific/), [LAURA](https://onco.cc/trials/laura/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Osimertinib](https://onco.cc/drugs/osimertinib/), [Proton therapy](https://onco.cc/technologies/proton-therapy/))
- Metastatic, EGFR exon 19 del / L858R: First line: osimertinib ± platinum-pemetrexed (FLAURA2) or amivantamab + lazertinib (MARIPOSA, OS benefit). Progression: re-biopsy/ctDNA; amivantamab + chemotherapy (MARIPOSA-2), Dato-DXd (TROPION-Lung05), platinum doublet; MET TKI add-on if MET-amplified; platinum-etoposide if small-cell transformation. ([Osimertinib](https://onco.cc/drugs/osimertinib/), [FLAURA2](https://onco.cc/trials/flaura2/), [Amivantamab](https://onco.cc/drugs/amivantamab/), [Lazertinib](https://onco.cc/drugs/lazertinib/), [MARIPOSA](https://onco.cc/trials/mariposa/), [Amivantamab + lazertinib (first-line EGFR NSCLC)](https://onco.cc/pairings/amivantamab-plus-lazertinib/), [Datopotamab deruxtecan](https://onco.cc/drugs/datopotamab-deruxtecan/), [TROPION-Lung05](https://onco.cc/trials/tropion-lung05/), [EGFR exon 19 deletion & L858R](https://onco.cc/terms/egfr-exon19-l858r/), [EGFR C797S](https://onco.cc/terms/c797s/), [MET amplification (bypass resistance)](https://onco.cc/terms/met-amplification/), [Histologic transformation](https://onco.cc/terms/histologic-transformation/))
- Metastatic, EGFR exon 20 insertion: Amivantamab + platinum-pemetrexed (PAPILLON); sunvozertinib later line. ([Amivantamab](https://onco.cc/drugs/amivantamab/), [EGFR exon 20 insertion](https://onco.cc/terms/egfr-exon20-insertion/))
- Metastatic, ALK-rearranged: Lorlatinib (CROWN; 5-year PFS 60%) or alectinib first line; on progression, neladalkib (under review) or lorlatinib if not used; local therapy for oligoprogression; chemotherapy. ([Lorlatinib](https://onco.cc/drugs/lorlatinib/), [CROWN](https://onco.cc/trials/crown/), [Alectinib](https://onco.cc/drugs/alectinib/), [Neladalkib](https://onco.cc/drugs/neladalkib/), [ALKOVE-1](https://onco.cc/trials/alkove-1/), [Oligoprogression](https://onco.cc/terms/oligoprogression/))
- Metastatic, ROS1-rearranged: Repotrectinib or zidesamtinib (2026) first line; entrectinib/crizotinib alternatives. ([Repotrectinib](https://onco.cc/drugs/repotrectinib/), [Zidesamtinib](https://onco.cc/drugs/zidesamtinib/), [ROS1](https://onco.cc/targets/ros1/))
- Metastatic, KRAS G12C: First line: PD-(L)1 ± chemotherapy by PD-L1 (G12C inhibitor + IO combinations in phase 3: olomorasib SUNRAY-01, divarasib Krascendo 2). Second line: sotorasib or adagrasib (CodeBreaK 200, KRYSTAL-12); divarasib superior head-to-head (Krascendo 1, 2026). ([Sotorasib](https://onco.cc/drugs/sotorasib/), [Adagrasib](https://onco.cc/drugs/adagrasib/), [Divarasib](https://onco.cc/drugs/divarasib/), [Olomorasib](https://onco.cc/drugs/olomorasib/), [CodeBreaK 200](https://onco.cc/trials/codebreak-200/), [KRYSTAL-12](https://onco.cc/trials/krystal-12/), [Krascendo 1](https://onco.cc/trials/krascendo-1/), [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/))
- Metastatic, BRAF V600E: Dabrafenib + trametinib or encorafenib + binimetinib first line; chemo-IO as alternative. ([Dabrafenib + trametinib](https://onco.cc/drugs/dabrafenib-trametinib/), [Encorafenib](https://onco.cc/drugs/encorafenib/), [BRAF](https://onco.cc/targets/braf/))
- Metastatic, MET exon 14 skipping: Capmatinib or tepotinib first line; telisotuzumab vedotin for c-Met-overexpressing EGFR-wild-type disease after chemotherapy (accelerated 2025). ([Capmatinib & tepotinib](https://onco.cc/drugs/capmatinib-tepotinib/), [Telisotuzumab vedotin](https://onco.cc/drugs/telisotuzumab-vedotin/), [TeliMET NSCLC-01](https://onco.cc/trials/telimet-nsclc-01/), [MET](https://onco.cc/targets/met/))
- Metastatic, RET-fusion: Selpercatinib first line (LIBRETTO-431); pralsetinib alternative. ([Selpercatinib](https://onco.cc/drugs/selpercatinib/), [LIBRETTO-431](https://onco.cc/trials/libretto-431/), [Pralsetinib](https://onco.cc/drugs/pralsetinib/), [RET](https://onco.cc/targets/ret/))
- Metastatic, HER2-mutant: First line: zongertinib (2026) or chemo-IO; sevabertinib (Nov 2025) or T-DXd after prior therapy. ([Zongertinib](https://onco.cc/drugs/zongertinib/), [Sevabertinib](https://onco.cc/drugs/sevabertinib/), [SOHO-01](https://onco.cc/trials/soho-01/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/), [HER2](https://onco.cc/targets/her2/))
- Metastatic, NTRK-fusion: Larotrectinib, entrectinib, or repotrectinib (tumour-agnostic). ([Repotrectinib](https://onco.cc/drugs/repotrectinib/), [NTRK](https://onco.cc/targets/ntrk/), [Tumour-agnostic (tissue-agnostic) approval](https://onco.cc/terms/tumour-agnostic/))
- Metastatic, driver-negative, PD-L1 TPS ≥50%: Pembrolizumab (KEYNOTE-024) or cemiplimab monotherapy; add chemotherapy for high burden or rapid progression. Ivonescimab beat pembrolizumab in China (HARMONi-2); not approved in the US. ([Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Cemiplimab](https://onco.cc/drugs/cemiplimab/), [KEYNOTE-024 & KEYNOTE-189](https://onco.cc/trials/keynote-024-189/), [Ivonescimab](https://onco.cc/drugs/ivonescimab/), [HARMONi-2](https://onco.cc/trials/harmoni-2/), [Tumour proportion score (TPS)](https://onco.cc/terms/tps/))
- Metastatic, driver-negative, PD-L1 TPS <50%: Pembrolizumab + platinum doublet (KEYNOTE-189 non-squamous; KEYNOTE-407 squamous); nivolumab + ipilimumab ± chemotherapy; tremelimumab + durvalumab + chemotherapy for PD-L1-negative or STK11/KEAP1-altered disease. Second line: docetaxel ± ramucirumab, TTFields, or trials of ADCs. ([Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Tremelimumab](https://onco.cc/drugs/tremelimumab/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [PD-1 blockade + chemotherapy in PD-L1-low NSCLC](https://onco.cc/pairings/pd1-plus-chemo-pdl1-low/), [Optune / Optune Pax (TTFields)](https://onco.cc/drugs/optune/))
- Metastatic, squamous: Pembrolizumab + carboplatin + (nab-)paclitaxel (KEYNOTE-407); no ADC approved (TROPION-Lung01 showed no benefit in squamous); ivonescimab + chemotherapy under study (HARMONi-3). ([Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [TROPION-Lung01](https://onco.cc/trials/tropion-lung01/), [HARMONi-3](https://onco.cc/trials/harmoni-3/))

## State of the art

- 5-year PFS 60% with lorlatinib in ALK+ disease.
- Adjuvant osimertinib after surgery for EGFR-mutant disease roughly halves the risk of the cancer returning or of dying from it (ADAURA).
- First regimen to beat osimertinib (MARIPOSA) and first to beat pembrolizumab (ivonescimab, China).
- Lorlatinib: 5-year PFS 60% in ALK-positive disease, the longest for any targeted therapy in metastatic solid tumours.
- Adjuvant osimertinib after surgery roughly halves the risk of dying from EGFR-mutant disease (ADAURA, OS HR 0.49); adjuvant alectinib cuts recurrence by 76% (ALINA).
- Amivantamab + lazertinib is the first regimen to beat osimertinib, with median OS more than 12 months longer (MARIPOSA).
- Perioperative chemo-immunotherapy improves survival in resectable disease (CheckMate 816, KEYNOTE-671).
- Twelve targetable drivers each have an approved matched therapy; two oral HER2 TKIs (zongertinib, sevabertinib) arrived in 2025-26.
- First-in-class bispecific ivonescimab beat pembrolizumab on PFS and OS in China; the US decision (PDUFA 14 Nov 2026) hinges on HARMONi.
- 5-year survival with pembrolizumab in PD-L1-high disease is ~32%, unthinkable a decade ago.

## Open problems

- Resistance to every TKI.
- Squamous histology has few targets.
- Screening uptake below 20% in the US.
- Screening uptake is under 20% in the US and lower elsewhere; never-smoker adenocarcinoma has no screening pathway.
- Resistance to every TKI is near-universal in metastatic disease; C797S has no approved fourth-generation EGFR inhibitor and small-cell transformation is undetectable by ctDNA.
- Squamous cell carcinoma has almost no targeted options and no approved ADC.
- KRAS G12C inhibitors add only ~1-2 months of PFS over docetaxel; non-G12C KRAS (G12D, G12V) remains undrugged outside trials.
- STK11/KEAP1 co-mutated and PD-L1-negative tumours respond poorly to immunotherapy.
- ADCs after TKI failure have not yet shown a survival benefit over platinum chemotherapy (HERTHENA-Lung02, TROPION-Lung01), and ILD limits combinations.
- Brain metastases occur in 30-50% of driver-positive patients; CNS activity now drives TKI choice, but leptomeningeal disease remains very hard to treat.
- Global access: most of the world's lung cancer patients never receive genomic profiling.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Non-small-cell_lung_cancer
- Wikipedia: https://en.wikipedia.org/wiki/Non-small-cell_lung_cancer

## Connected records

- cancers: [Adenocarcinoma in situ and minimally invasive adenocarcinoma of the lung](https://onco.cc/cancers/lung-adenocarcinoma-in-situ-and-minimally-invasive/), [Adenocarcinoma of the lung](https://onco.cc/cancers/lung-adenocarcinoma/), [Adenosquamous carcinoma of the lung](https://onco.cc/cancers/lung-adenosquamous-carcinoma/), [ALK-positive non-small-cell lung cancer](https://onco.cc/cancers/alk-positive-nsclc/), [Basaloid squamous cell carcinoma of the lung](https://onco.cc/cancers/basaloid-squamous-cell-carcinoma-lung/), [BRAF V600E-mutant non-small-cell lung cancer](https://onco.cc/cancers/braf-v600e-nsclc/), [Brain metastases (secondary brain tumours)](https://onco.cc/cancers/secondary-brain-tumours/), [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [HER2-mutant non-small-cell lung cancer](https://onco.cc/cancers/her2-mutant-nsclc/), [Invasive mucinous adenocarcinoma of the lung](https://onco.cc/cancers/invasive-mucinous-adenocarcinoma-lung/), [KRAS G12C-mutant non-small-cell lung cancer](https://onco.cc/cancers/kras-g12c-nsclc/), [Large cell carcinoma of the lung](https://onco.cc/cancers/large-cell-lung-carcinoma/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Lymphoepithelial carcinoma of the lung](https://onco.cc/cancers/lymphoepithelial-carcinoma-lung/), [MET exon 14 and MET-amplified non-small-cell lung cancer](https://onco.cc/cancers/met-altered-nsclc/), [NTRK fusion-positive non-small-cell lung cancer](https://onco.cc/cancers/ntrk-fusion-nsclc/), [PD-L1-high non-small-cell lung cancer without a driver mutation](https://onco.cc/cancers/pdl1-high-nsclc/), [Pulmonary blastoma (adult)](https://onco.cc/cancers/pulmonary-blastoma/), [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/), [RET fusion-positive non-small-cell lung cancer](https://onco.cc/cancers/ret-fusion-nsclc/), [ROS1-positive non-small-cell lung cancer](https://onco.cc/cancers/ros1-positive-nsclc/), [Sarcomatoid carcinoma of the lung](https://onco.cc/cancers/pulmonary-sarcomatoid-carcinoma/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/), [Squamous cell carcinoma of the lung](https://onco.cc/cancers/lung-squamous-cell-carcinoma/), [Unresectable stage III non-small-cell lung cancer](https://onco.cc/cancers/stage-iii-unresectable-nsclc/)
- roadmaps: [ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs](https://onco.cc/roadmaps/adc-generations/), [Immunotherapy roadmap: Coley's toxins → checkpoint inhibitors → engineered immunity](https://onco.cc/roadmaps/immunotherapy-roadmap/), [KRAS roadmap: undruggable → G12C → pan-RAS](https://onco.cc/roadmaps/kras-roadmap/), [TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET](https://onco.cc/roadmaps/trop2-adc-roadmap/)
- pairings: [ADC + checkpoint inhibitor](https://onco.cc/pairings/adc-plus-io/), [Amivantamab + lazertinib (first-line EGFR NSCLC)](https://onco.cc/pairings/amivantamab-plus-lazertinib/), [BRAF inhibitor + MEK inhibitor](https://onco.cc/pairings/braf-plus-mek/), [Caution: proton therapy vs IMRT](https://onco.cc/pairings/proton-vs-imrt/), [Caution: TIGIT + PD-(L)1 blockade](https://onco.cc/pairings/tigit-plus-pd1-caution/), [EGFR TKI → ADC on progression](https://onco.cc/pairings/tki-then-adc-lung/), [PD-1 blockade + chemotherapy in PD-L1-low NSCLC](https://onco.cc/pairings/pd1-plus-chemo-pdl1-low/), [PD-1 blockade + VEGF inhibition](https://onco.cc/pairings/io-plus-vegf/), [Radiotherapy + immunotherapy](https://onco.cc/pairings/radiation-plus-io/), [Sequence: targeted therapy before immunotherapy in driver-positive NSCLC](https://onco.cc/pairings/targeted-before-io-nsclc/), [TROP2 PET → TROP2 ADC selection](https://onco.cc/pairings/trop2-pet-to-adc/)
- technologies: [AI in radiology](https://onco.cc/technologies/radiology-ai-screening/), [AI scoring of biomarkers and grade on pathology slides](https://onco.cc/technologies/ai-pathology-scoring/), [Alternative medicine used instead of standard treatment](https://onco.cc/technologies/alternative-medicine-instead-of-treatment/), [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [ATR and CHK1 inhibitors](https://onco.cc/technologies/atr-chk1-inhibitors/), [Biology-guided radiotherapy (RefleXion X1, SCINTIX)](https://onco.cc/technologies/biology-guided-radiotherapy/), [Bispecific ADC](https://onco.cc/technologies/bispecific-adc/), [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [Bone-modifying agents (bisphosphonates, denosumab)](https://onco.cc/technologies/bone-modifying-agents/), [Breath and volatile-organic-compound detection](https://onco.cc/technologies/breath-vocs/), [C-arm medical linear accelerators (TrueBeam, Versa HD and others)](https://onco.cc/technologies/c-arm-linac/), [Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine](https://onco.cc/technologies/cachexia-appetite-pharmacotherapy/), [Cachexia-directed therapy (GDF-15 blockade)](https://onco.cc/technologies/cachexia-therapy/), [Cancer-associated thrombosis prevention and treatment](https://onco.cc/technologies/cancer-associated-thrombosis/), [cfDNA fragmentomics](https://onco.cc/technologies/fragmentomics/), [Clonal evolution and branching models](https://onco.cc/technologies/clonal-evolution-models/), [Closed-system transfer devices for hazardous drugs (PhaSeal, ChemoLock, Equashield)](https://onco.cc/technologies/closed-system-transfer-devices/), [Comprehensive genomic profiling](https://onco.cc/technologies/cgp/), [Cryoablation systems](https://onco.cc/technologies/cryoablation-systems/), [CT (computed tomography)](https://onco.cc/technologies/ct/), [CT body composition and sarcopenia measurement](https://onco.cc/technologies/ct-body-composition-sarcopenia/), [CyberKnife robotic radiosurgery](https://onco.cc/technologies/cyberknife/), [Dietary fibre and the gut microbiome for immunotherapy response](https://onco.cc/technologies/dietary-fibre-microbiome-io/), [Dietary supplements during cancer treatment: interactions and harms](https://onco.cc/technologies/dietary-supplements-treatment-interactions/), [Early integrated palliative care](https://onco.cc/technologies/palliative-care/), [Endoscopic ultrasound and EBUS systems](https://onco.cc/technologies/endoscopic-ultrasound-systems/), [Exercise during chemotherapy and radiotherapy](https://onco.cc/technologies/exercise-during-chemotherapy/), [Faecal microbiota transplantation for PD-1 non-responders](https://onco.cc/technologies/fmt-checkpoint-nonresponders/), [Fish oil (EPA) for cancer weight loss](https://onco.cc/technologies/omega3-epa-cachexia/), [G8 geriatric screening tool](https://onco.cc/technologies/g8-geriatric-screening/), [Generic sterile injectables (the 2023 platinum shortage)](https://onco.cc/technologies/sterile-injectable-generics-manufacturing/), [Genetically engineered mouse models](https://onco.cc/technologies/genetically-engineered-mouse-models/), [Hydrazine sulfate](https://onco.cc/technologies/hydrazine-sulfate/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Immuno-PET](https://onco.cc/technologies/immuno-pet/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [In-room imaging for radiotherapy (cone-beam CT, ExacTrac, CT-on-rails, HyperSight)](https://onco.cc/technologies/in-room-imaging-systems/), [Intraoperative fluorescence and Cerenkov imaging systems (SPY, Firefly, LumiSystem, LightPath)](https://onco.cc/technologies/intraoperative-fluorescence-imaging-systems/), [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Low-dose CT lung screening](https://onco.cc/technologies/low-dose-ct-screening/), [Microwave and radiofrequency ablation systems](https://onco.cc/technologies/microwave-rf-ablation/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/), [mRNA and lipid nanoparticle manufacturing](https://onco.cc/technologies/mrna-lnp-manufacturing/), [MUSK (Stanford, vision-language pathology)](https://onco.cc/technologies/musk/), [NHS Targeted Lung Health Check (lung cancer screening programme)](https://onco.cc/technologies/nhs-targeted-lung-health-check/), [Nutrition support and cachexia management](https://onco.cc/technologies/oncology-nutrition/), [Oncology information and record-and-verify systems (ARIA, MOSAIQ)](https://onco.cc/technologies/oncology-information-systems/), [Oncology nutrition assessment and medical nutrition therapy](https://onco.cc/technologies/nutrition-screening-mnt/), [Palliative radiotherapy](https://onco.cc/technologies/palliative-radiotherapy/), [Parsortix label-free circulating tumour cell harvest](https://onco.cc/technologies/parsortix-ctc-harvest/), [Patient positioning and surface guidance systems (AlignRT, Catalyst, ExacTrac Dynamic)](https://onco.cc/technologies/patient-positioning-surface-guidance-systems/), [Personalised neoantigen (mRNA) vaccines](https://onco.cc/technologies/neoantigen-mrna-vaccine/), [Photon-counting CT](https://onco.cc/technologies/photon-counting-ct/), [Platinum agents](https://onco.cc/technologies/platinum/), [Prehabilitation before cancer surgery](https://onco.cc/technologies/prehabilitation/), [Probiotics, antibiotics and stewardship around immunotherapy](https://onco.cc/technologies/probiotics-antibiotic-stewardship-io/), [Proton therapy](https://onco.cc/technologies/proton-therapy/), [Quantitative imaging biomarkers (RECIST, PERCIST, SUV, ADC)](https://onco.cc/technologies/quantitative-imaging-biomarkers/), [Radiotherapy QA phantoms and dosimeters (Sun Nuclear, IBA Dosimetry, PTW)](https://onco.cc/technologies/radiotherapy-qa-phantoms-dosimeters/), [Residual disease kinetics (BCR-ABL halving and ctDNA slopes)](https://onco.cc/technologies/mrd-kinetics-models/), [Resistance training and protein for cachexia and sarcopenia](https://onco.cc/technologies/resistance-training-cachexia/), [Respiratory gating and tumour tracking systems (RPM, ABC, Calypso, Synchrony)](https://onco.cc/technologies/respiratory-gating-tumour-tracking-systems/), [Respiratory motion management (4D-CT, gating, breath-hold, tracking)](https://onco.cc/technologies/respiratory-motion-management/), [Robotic & minimally invasive surgery](https://onco.cc/technologies/robotic-surgery/), [Robotic and navigational bronchoscopy](https://onco.cc/technologies/robotic-bronchoscopy/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/), [Shark cartilage (AE-941, Neovastat)](https://onco.cc/technologies/shark-cartilage/), [Sleep and circadian interventions in cancer](https://onco.cc/technologies/sleep-circadian-interventions/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/), [Smoking cessation in cancer patients](https://onco.cc/technologies/smoking-cessation-after-diagnosis/), [Stereotactic ablative radiotherapy for oligometastatic disease](https://onco.cc/technologies/sabr-oligometastases/), [Surgical robots: da Vinci, Hugo, Versius and single-port systems](https://onco.cc/technologies/surgical-robot-platforms/), [Sybil (MIT/MGH lung cancer risk from CT)](https://onco.cc/technologies/sybil/), [The four Rs and accelerated repopulation](https://onco.cc/technologies/fractionation-repopulation-models/), [TIGIT blockade](https://onco.cc/technologies/tigit-blockade/), [TIL therapy](https://onco.cc/technologies/til-therapy/), [TIM-3 blockade](https://onco.cc/technologies/tim3-blockade/), [TROP2 PET](https://onco.cc/technologies/trop2-pet/), [Troponin and natriuretic peptide monitoring during cancer treatment](https://onco.cc/technologies/cardiac-biomarker-monitoring/), [Tumour clonal evolution tracking](https://onco.cc/technologies/clonal-evolution-tracking/), [Tumour treating fields (TTFields)](https://onco.cc/technologies/ttfields/), [Tumour volume doubling time](https://onco.cc/technologies/tumour-doubling-time/)
- targets: [ABCB1](https://onco.cc/targets/abcb1/), [ABCC10](https://onco.cc/targets/abcc10/), [ABL2](https://onco.cc/targets/abl2/), [ACTA1](https://onco.cc/targets/acta1/), [ACTL6A](https://onco.cc/targets/actl6a/), [ACVR1B](https://onco.cc/targets/acvr1b/), [Adenosine A2A receptor (ADORA2A)](https://onco.cc/targets/adora2a/), [AFF3](https://onco.cc/targets/aff3/), [ALK](https://onco.cc/targets/alk/), [ANK1](https://onco.cc/targets/ank1/), [ARAF](https://onco.cc/targets/araf/), [AREG](https://onco.cc/targets/areg/), [ARHGEF10](https://onco.cc/targets/arhgef10/), [ATF7IP](https://onco.cc/targets/atf7ip/), [ATR](https://onco.cc/targets/atr/), [AURKA](https://onco.cc/targets/aurka/), [BARD1](https://onco.cc/targets/bard1/), [BIRC3](https://onco.cc/targets/birc3/), [BIRC5](https://onco.cc/targets/birc5/), [BRAF](https://onco.cc/targets/braf/), [CBL](https://onco.cc/targets/cbl/), [CBLB](https://onco.cc/targets/cblb/), [CCDC6](https://onco.cc/targets/ccdc6/), [CCND2](https://onco.cc/targets/ccnd2/), [CCND3](https://onco.cc/targets/ccnd3/), [CD137 (4-1BB, TNFRSF9)](https://onco.cc/targets/cd137/), [CD209](https://onco.cc/targets/cd209/), [CD73 / adenosine axis](https://onco.cc/targets/cd73-adenosine/), [CD74](https://onco.cc/targets/cd74/), [CD80 (B7-1)](https://onco.cc/targets/cd80/), [CD96](https://onco.cc/targets/cd96/), [CDH10](https://onco.cc/targets/cdh10/), [CEACAM5](https://onco.cc/targets/ceacam5/), [CIC](https://onco.cc/targets/cic/), [Claudin 6](https://onco.cc/targets/cldn6/), [CLIP1](https://onco.cc/targets/clip1/), [CMTR2](https://onco.cc/targets/cmtr2/), [CRKL](https://onco.cc/targets/crkl/), [CRLF2](https://onco.cc/targets/crlf2/), [CTLA-4](https://onco.cc/targets/ctla4/), [CTNNA2](https://onco.cc/targets/ctnna2/), [CTNND2](https://onco.cc/targets/ctnnd2/), [CUL3](https://onco.cc/targets/cul3/), [CX3CL1](https://onco.cc/targets/cx3cl1/), [DCAF12L2](https://onco.cc/targets/dcaf12l2/), [DDR2 receptor kinase](https://onco.cc/targets/ddr2/), [DICER1](https://onco.cc/targets/dicer1/), [DNA polymerase alpha (POLA1)](https://onco.cc/targets/pola1/), [DROSHA](https://onco.cc/targets/drosha/), [EBF1](https://onco.cc/targets/ebf1/), [EGFR](https://onco.cc/targets/egfr/), [EML4](https://onco.cc/targets/eml4/), [EPHA7](https://onco.cc/targets/epha7/), [ERCC1](https://onco.cc/targets/ercc1/), [ERCC2](https://onco.cc/targets/ercc2/), [ERCC3](https://onco.cc/targets/ercc3/), [ERCC4](https://onco.cc/targets/ercc4/), [ERCC5](https://onco.cc/targets/ercc5/), [EREG](https://onco.cc/targets/ereg/), [ERRFI1](https://onco.cc/targets/errfi1/), [ETS2](https://onco.cc/targets/ets2/), [FAK (PTK2)](https://onco.cc/targets/fak/), [FAM135B](https://onco.cc/targets/fam135b/), [FGFR1](https://onco.cc/targets/fgfr1/), [FLCN](https://onco.cc/targets/flcn/), [Folate receptor alpha](https://onco.cc/targets/folr1/), [FOXO1](https://onco.cc/targets/foxo1/), [GART (trifunctional purine synthesis enzyme)](https://onco.cc/targets/gart/), [GNAQ](https://onco.cc/targets/gnaq/), [HER2](https://onco.cc/targets/her2/), [HER3](https://onco.cc/targets/her3/), [HER4 (ERBB4)](https://onco.cc/targets/erbb4/), [HGF](https://onco.cc/targets/hgf/), [IGF-1 receptor (IGF1R)](https://onco.cc/targets/igf1r/), [IRS4](https://onco.cc/targets/irs4/), [JAK3](https://onco.cc/targets/jak3/), [KEAP1](https://onco.cc/targets/keap1/), [KIF5B](https://onco.cc/targets/kif5b/), [KLF5](https://onco.cc/targets/klf5/), [KMT2B](https://onco.cc/targets/kmt2b/), [KRAS](https://onco.cc/targets/kras/), [LATS2](https://onco.cc/targets/lats2/), [LRIG3](https://onco.cc/targets/lrig3/), [MACC1](https://onco.cc/targets/macc1/), [MAML2](https://onco.cc/targets/maml2/), [MAPK1](https://onco.cc/targets/mapk1/), [MB21D2](https://onco.cc/targets/mb21d2/), [MEK1/2](https://onco.cc/targets/mek/), [MET](https://onco.cc/targets/met/), [MGA](https://onco.cc/targets/mga/), [MIR21](https://onco.cc/targets/mir21/), [MUC6](https://onco.cc/targets/muc6/), [NCOA2](https://onco.cc/targets/ncoa2/), [NFKBIE](https://onco.cc/targets/nfkbie/), [NIPBL](https://onco.cc/targets/nipbl/), [NKG2A (KLRC1)](https://onco.cc/targets/klrc1/), [NRK](https://onco.cc/targets/nrk/), [NSD3](https://onco.cc/targets/nsd3/), [NTRK](https://onco.cc/targets/ntrk/), [NUP98](https://onco.cc/targets/nup98/), [NUTM1](https://onco.cc/targets/nutm1/), [PABPC1](https://onco.cc/targets/pabpc1/), [PAPPA2](https://onco.cc/targets/pappa2/), [PARP4](https://onco.cc/targets/parp4/), [PBK](https://onco.cc/targets/pbk/), [PBX1](https://onco.cc/targets/pbx1/), [PD-1](https://onco.cc/targets/pd1/), [PD-L1](https://onco.cc/targets/pdl1/), [PER3](https://onco.cc/targets/per3/), [PHF6](https://onco.cc/targets/phf6/), [PIM1](https://onco.cc/targets/pim1/), [POLE4](https://onco.cc/targets/pole4/), [PPM1D](https://onco.cc/targets/ppm1d/), [PRAME](https://onco.cc/targets/prame/), [PRKDC](https://onco.cc/targets/prkdc/), [PRMT5 (MTAP-deleted cancers)](https://onco.cc/targets/prmt5-mtap/), [PSPC1](https://onco.cc/targets/pspc1/), [PTPRF](https://onco.cc/targets/ptprf/), [PTPRK](https://onco.cc/targets/ptprk/), [PXDNL](https://onco.cc/targets/pxdnl/), [RAD21](https://onco.cc/targets/rad21/), [RANBP2](https://onco.cc/targets/ranbp2/), [RASA1](https://onco.cc/targets/rasa1/), [RBM10](https://onco.cc/targets/rbm10/), [RBM15](https://onco.cc/targets/rbm15/), [RET](https://onco.cc/targets/ret/), [RGPD3](https://onco.cc/targets/rgpd3/), [RGS7](https://onco.cc/targets/rgs7/), [RHPN2](https://onco.cc/targets/rhpn2/), [Ribonucleotide reductase (RRM1)](https://onco.cc/targets/rrm1/), [RICTOR](https://onco.cc/targets/rictor/), [RIT1](https://onco.cc/targets/rit1/), [RON receptor (MST1R)](https://onco.cc/targets/ron/), [ROS1](https://onco.cc/targets/ros1/), [RPL5](https://onco.cc/targets/rpl5/), [SCN8A](https://onco.cc/targets/scn8a/), [SDC4](https://onco.cc/targets/sdc4/), [SETD1B](https://onco.cc/targets/setd1b/), [SHP2 (PTPN11)](https://onco.cc/targets/shp2/), [SLC34A2](https://onco.cc/targets/slc34a2/), [SUSD2](https://onco.cc/targets/susd2/), [TCF3](https://onco.cc/targets/tcf3/), [TFRC](https://onco.cc/targets/tfrc/), [TIGIT](https://onco.cc/targets/tigit/), [TIM-3](https://onco.cc/targets/tim3/), [TNC](https://onco.cc/targets/tnc/), [TPM3](https://onco.cc/targets/tpm3/), [TROP2](https://onco.cc/targets/trop2/), [TSC1](https://onco.cc/targets/tsc1/), [TTF1](https://onco.cc/targets/ttf1/), [Tubulin (microtubules)](https://onco.cc/targets/tubulin/), [USP8](https://onco.cc/targets/usp8/), [VAV1](https://onco.cc/targets/vav1/), [VEGF / VEGFR](https://onco.cc/targets/vegf/), [VISTA](https://onco.cc/targets/vista/), [XRCC1](https://onco.cc/targets/xrcc1/), [ZEB1](https://onco.cc/targets/zeb1/), [ZMYM3](https://onco.cc/targets/zmym3/), [ZNF395](https://onco.cc/targets/znf395/), [ZNF750](https://onco.cc/targets/znf750/)
- drugs: [ABBV-706](https://onco.cc/drugs/abbv-706/), [ABSK061](https://onco.cc/drugs/absk061/), [Acasunlimab](https://onco.cc/drugs/acasunlimab/), [Adagrasib](https://onco.cc/drugs/adagrasib/), [Afatinib](https://onco.cc/drugs/afatinib/), [Aglatimagene besadenovec](https://onco.cc/drugs/aglatimagene-besadenovec/), [AK117](https://onco.cc/drugs/ak117/), [AK146D1](https://onco.cc/drugs/ak146d1/), [AL8326](https://onco.cc/drugs/al8326/), [Alectinib](https://onco.cc/drugs/alectinib/), [Amivantamab](https://onco.cc/drugs/amivantamab/), [Amrubicin](https://onco.cc/drugs/amrubicin/), [AMT-116](https://onco.cc/drugs/amt-116/), [Anlotinib](https://onco.cc/drugs/anlotinib/), [Anvumetostat](https://onco.cc/drugs/anvumetostat/), [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Atigotatug](https://onco.cc/drugs/atigotatug/), [AU-007](https://onco.cc/drugs/au-007/), [Aumolertinib](https://onco.cc/drugs/aumolertinib/), [AZD7789](https://onco.cc/drugs/azd7789/), [BA3071](https://onco.cc/drugs/ba3071/), [Befotertinib](https://onco.cc/drugs/befotertinib/), [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Binimetinib](https://onco.cc/drugs/binimetinib/), [BNT324](https://onco.cc/drugs/bnt324/), [Boserolimab](https://onco.cc/drugs/boserolimab/), [Brenetafusp](https://onco.cc/drugs/brenetafusp/), [Brigatinib](https://onco.cc/drugs/brigatinib/), [Budigalimab](https://onco.cc/drugs/budigalimab/), [Calderasib](https://onco.cc/drugs/calderasib/), [Camrelizumab](https://onco.cc/drugs/camrelizumab/), [Capmatinib](https://onco.cc/drugs/capmatinib/), [Capmatinib & tepotinib](https://onco.cc/drugs/capmatinib-tepotinib/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cemiplimab](https://onco.cc/drugs/cemiplimab/), [Ceralasertib](https://onco.cc/drugs/ceralasertib/), [Ceritinib](https://onco.cc/drugs/ceritinib/), [Cetrelimab](https://onco.cc/drugs/cetrelimab/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [cobas EGFR Mutation Test v2](https://onco.cc/drugs/cobas-egfr-mutation-test/), [Cobolimab](https://onco.cc/drugs/cobolimab/), [Crizotinib](https://onco.cc/drugs/crizotinib/), [Dabrafenib](https://onco.cc/drugs/dabrafenib/), [Dabrafenib + trametinib](https://onco.cc/drugs/dabrafenib-trametinib/), [Dacomitinib](https://onco.cc/drugs/dacomitinib/), [Daraxonrasib](https://onco.cc/drugs/daraxonrasib/), [Datopotamab deruxtecan](https://onco.cc/drugs/datopotamab-deruxtecan/), [Denosumab](https://onco.cc/drugs/denosumab/), [Divarasib](https://onco.cc/drugs/divarasib/), [DJI136](https://onco.cc/drugs/dji136/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Domvanalimab](https://onco.cc/drugs/domvanalimab/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [EIK1001](https://onco.cc/drugs/eik1001/), [Elironrasib](https://onco.cc/drugs/elironrasib/), [Encorafenib](https://onco.cc/drugs/encorafenib/), [Ensartinib](https://onco.cc/drugs/ensartinib/), [Entrectinib](https://onco.cc/drugs/entrectinib/), [ENV-501](https://onco.cc/drugs/env-501/), [EP0031](https://onco.cc/drugs/ep0031/), [Erlotinib](https://onco.cc/drugs/erlotinib/), [Fulzerasib](https://onco.cc/drugs/fulzerasib/), [Furmonertinib](https://onco.cc/drugs/furmonertinib/), [Garsorasib](https://onco.cc/drugs/garsorasib/), [Gefitinib](https://onco.cc/drugs/gefitinib/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [GFH375](https://onco.cc/drugs/gfh375/), [Glecirasib](https://onco.cc/drugs/glecirasib/), [Glumetinib](https://onco.cc/drugs/glumetinib/), [Gotistobart](https://onco.cc/drugs/gotistobart/), [Guardant Reveal](https://onco.cc/drugs/guardant-reveal/), [Guardant360 CDx](https://onco.cc/drugs/guardant360-cdx/), [HB0036](https://onco.cc/drugs/hb0036/), [HLX26](https://onco.cc/drugs/hlx26/), [HLX43](https://onco.cc/drugs/hlx43/), [HMBD-001](https://onco.cc/drugs/hmbd-001/), [HS-20093](https://onco.cc/drugs/hs-20093/), [HS-20117](https://onco.cc/drugs/hs-20117/), [IBI363](https://onco.cc/drugs/ibi363/), [Icotinib](https://onco.cc/drugs/icotinib/), [IN10018](https://onco.cc/drugs/in10018/), [Iniparib](https://onco.cc/drugs/iniparib/), [Intismeran autogene](https://onco.cc/drugs/intismeran-autogene/), [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Iruplinalkib](https://onco.cc/drugs/iruplinalkib/), [Ivonescimab](https://onco.cc/drugs/ivonescimab/), [Izalontamab brengitecan](https://onco.cc/drugs/izalontamab-brengitecan/), [JDQ443](https://onco.cc/drugs/jdq443/), [JK08](https://onco.cc/drugs/jk08/), [JMT101](https://onco.cc/drugs/jmt101/), [JMT203](https://onco.cc/drugs/jmt203/), [JS111](https://onco.cc/drugs/js111/), [JYP0015](https://onco.cc/drugs/jyp0015/), [KL-A167](https://onco.cc/drugs/kl-a167/), [Larotrectinib](https://onco.cc/drugs/larotrectinib/), [Lazertinib](https://onco.cc/drugs/lazertinib/), [Lifileucel](https://onco.cc/drugs/lifileucel/), [Limertinib](https://onco.cc/drugs/limertinib/), [Livmoniplimab](https://onco.cc/drugs/livmoniplimab/), [Lorlatinib](https://onco.cc/drugs/lorlatinib/), [LP-184](https://onco.cc/drugs/lp-184/), [Mavrostobart](https://onco.cc/drugs/mavrostobart/), [MCLA-129](https://onco.cc/drugs/mcla-129/), [MI Cancer Seek](https://onco.cc/drugs/caris-mi-cancer-seek/), [Mobocertinib](https://onco.cc/drugs/mobocertinib/), [Monalizumab](https://onco.cc/drugs/monalizumab/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/), [Navlimetostat](https://onco.cc/drugs/navlimetostat/), [Necitumumab](https://onco.cc/drugs/necitumumab/), [Nedaplatin](https://onco.cc/drugs/nedaplatin/), [Neladalkib](https://onco.cc/drugs/neladalkib/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Oleclumab](https://onco.cc/drugs/oleclumab/), [Olmutinib](https://onco.cc/drugs/olmutinib/), [Olomorasib](https://onco.cc/drugs/olomorasib/), [Olvimulogene nanivacirepvec](https://onco.cc/drugs/olvimulogene-nanivacirepvec/), [Oncomine Dx Target Test](https://onco.cc/drugs/oncomine-dx-target-test/), [Optellum Virtual Nodule Clinic](https://onco.cc/drugs/optellum-virtual-nodule-clinic/), [Optune / Optune Pax (TTFields)](https://onco.cc/drugs/optune/), [OR502](https://onco.cc/drugs/or502/), [OSE2101](https://onco.cc/drugs/ose2101/), [Osimertinib](https://onco.cc/drugs/osimertinib/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pafolacianine](https://onco.cc/drugs/pafolacianine/), [Palacaparib](https://onco.cc/drugs/palacaparib/), [Patritumab deruxtecan](https://onco.cc/drugs/patritumab-deruxtecan/), [PD-L1 IHC 22C3 pharmDx](https://onco.cc/drugs/dako-pd-l1-22c3-pharmdx/), [Peluntamig](https://onco.cc/drugs/peluntamig/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/), [PF-07248144](https://onco.cc/drugs/pf-07248144/), [PF-08046054](https://onco.cc/drugs/pf-08046054/), [PF-08634404](https://onco.cc/drugs/pf-08634404/), [PM8002](https://onco.cc/drugs/pm8002/), [Porfimer sodium](https://onco.cc/drugs/porfimer-sodium/), [Pralsetinib](https://onco.cc/drugs/pralsetinib/), [QL1706](https://onco.cc/drugs/ql1706/), [QL2107](https://onco.cc/drugs/ql2107/), [QLC5508](https://onco.cc/drugs/qlc5508/), [Quemliclustat](https://onco.cc/drugs/quemliclustat/), [RaDaR](https://onco.cc/drugs/radar-mrd/), [Ramucirumab](https://onco.cc/drugs/ramucirumab/), [RC148](https://onco.cc/drugs/rc148/), [Recombinant human endostatin](https://onco.cc/drugs/recombinant-human-endostatin/), [REGN7075](https://onco.cc/drugs/regn7075/), [Repotrectinib](https://onco.cc/drugs/repotrectinib/), [Resolution ctDx FIRST](https://onco.cc/drugs/resolution-ctdx-first/), [Rilvegostomig](https://onco.cc/drugs/rilvegostomig/), [Roginolisib](https://onco.cc/drugs/roginolisib/), [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/), [Samarium-153 lexidronam](https://onco.cc/drugs/samarium-153-lexidronam/), [Saruparib](https://onco.cc/drugs/saruparib/), [Savolitinib](https://onco.cc/drugs/savolitinib/), [SCTB14](https://onco.cc/drugs/sctb14/), [SCTB41](https://onco.cc/drugs/sctb41/), [Selpercatinib](https://onco.cc/drugs/selpercatinib/), [Setidegrasib](https://onco.cc/drugs/setidegrasib/), [Sevabertinib](https://onco.cc/drugs/sevabertinib/), [SHR-8068](https://onco.cc/drugs/shr-8068/), [SHR-A2009](https://onco.cc/drugs/shr-a2009/), [SHR-A2102](https://onco.cc/drugs/shr-a2102/), [SI-B001](https://onco.cc/drugs/si-b001/), [Signatera](https://onco.cc/drugs/signatera/), [Silevertinib](https://onco.cc/drugs/silevertinib/), [Sintilimab](https://onco.cc/drugs/sintilimab/), [Sitneprotafib](https://onco.cc/drugs/sitneprotafib/), [Sotorasib](https://onco.cc/drugs/sotorasib/), [SSGJ-706](https://onco.cc/drugs/ssgj-706/), [Sugemalimab](https://onco.cc/drugs/sugemalimab/), [Sunvozertinib](https://onco.cc/drugs/sunvozertinib/), [SYS6010](https://onco.cc/drugs/sys6010/), [T3011](https://onco.cc/drugs/t3011/), [TAK-928](https://onco.cc/drugs/tak-928/), [Talc (intrapleural)](https://onco.cc/drugs/talc-sclerosant/), [Taletrectinib](https://onco.cc/drugs/taletrectinib/), [Telisotuzumab adizutecan](https://onco.cc/drugs/telisotuzumab-adizutecan/), [Telisotuzumab vedotin](https://onco.cc/drugs/telisotuzumab-vedotin/), [Tepotinib](https://onco.cc/drugs/tepotinib/), [TGRX-326](https://onco.cc/drugs/tgrx-326/), [therascreen companion diagnostic kits (KRAS, EGFR, PIK3CA, FGFR, BRAF)](https://onco.cc/drugs/therascreen-cdx/), [Tilatamig samrotecan](https://onco.cc/drugs/tilatamig-samrotecan/), [Tiragolumab](https://onco.cc/drugs/tiragolumab/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/), [TNG260](https://onco.cc/drugs/tng260/), [TNG456](https://onco.cc/drugs/tng456/), [TNG462](https://onco.cc/drugs/tng462/), [TNO155](https://onco.cc/drugs/tno155/), [TQB2102](https://onco.cc/drugs/tqb2102/), [TQB2450](https://onco.cc/drugs/tqb2450/), [TQB6411](https://onco.cc/drugs/tqb6411/), [Trametinib](https://onco.cc/drugs/trametinib/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/), [Trastuzumab rezetecan](https://onco.cc/drugs/trastuzumab-rezetecan/), [Tremelimumab](https://onco.cc/drugs/tremelimumab/), [TRI-611](https://onco.cc/drugs/tri-611/), [Tusamitamab ravtansine](https://onco.cc/drugs/tusamitamab-ravtansine/), [TY-9591](https://onco.cc/drugs/ty-9591/), [Uliledlimab](https://onco.cc/drugs/uliledlimab/), [Upifitamab rilsodotin](https://onco.cc/drugs/upifitamab-rilsodotin/), [Vebreltinib](https://onco.cc/drugs/vebreltinib/), [VENTANA PD-L1 (SP142) Assay](https://onco.cc/drugs/ventana-pd-l1-sp142/), [VENTANA PD-L1 (SP263) Assay](https://onco.cc/drugs/ventana-pd-l1-sp263/), [Vibostolimab](https://onco.cc/drugs/vibostolimab/), [Vindesine](https://onco.cc/drugs/vindesine/), [Vinorelbine](https://onco.cc/drugs/vinorelbine/), [Vistusertib](https://onco.cc/drugs/vistusertib/), [VRN110755](https://onco.cc/drugs/vrn110755/), [VS-7375](https://onco.cc/drugs/vs-7375/), [XNW27011](https://onco.cc/drugs/xnw27011/), [YL201](https://onco.cc/drugs/yl201/), [YL202](https://onco.cc/drugs/yl202/), [Zenocutuzumab](https://onco.cc/drugs/zenocutuzumab/), [ZG006](https://onco.cc/drugs/zg006/), [Zidesamtinib](https://onco.cc/drugs/zidesamtinib/), [Zipalertinib](https://onco.cc/drugs/zipalertinib/), [ZL-1310](https://onco.cc/drugs/zl-1310/), [Zoldonrasib](https://onco.cc/drugs/zoldonrasib/), [Zoledronic acid](https://onco.cc/drugs/zoledronic-acid/), [Zongertinib](https://onco.cc/drugs/zongertinib/)
- companies: [A2 Biotherapeutics](https://onco.cc/companies/a2-biotherapeutics/), [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/), [Achieve Life Sciences (formerly OncoGenex)](https://onco.cc/companies/achieve-life-sciences/), [Actinium Pharmaceuticals](https://onco.cc/companies/actinium-pharmaceuticals/), [Advenchen Laboratories](https://onco.cc/companies/advenchen-laboratories/), [Adventris Pharmaceuticals](https://onco.cc/companies/adventris-pharmaceuticals/), [Agennix](https://onco.cc/companies/agennix/), [Akeso](https://onco.cc/companies/akeso/), [Amgen](https://onco.cc/companies/amgen/), [Amphista Therapeutics](https://onco.cc/companies/amphista-therapeutics/), [Anbogen Therapeutics](https://onco.cc/companies/anbogen-therapeutics/), [ANGLE plc](https://onco.cc/companies/angle-plc/), [Aosaikang Pharmaceutical](https://onco.cc/companies/aosaikang-pharmaceutical/), [AP Biosciences](https://onco.cc/companies/ap-biosciences/), [Apollomics](https://onco.cc/companies/apollomics/), [Arcus Biosciences](https://onco.cc/companies/arcus-biosciences/), [ArriVent BioPharma](https://onco.cc/companies/arrivent/), [AstraZeneca](https://onco.cc/companies/astrazeneca/), [Avistone Biotechnology](https://onco.cc/companies/avistone-biotechnology/), [Bayer](https://onco.cc/companies/bayer/), [BeyondSpring Pharmaceuticals](https://onco.cc/companies/beyondspring/), [Biodesix](https://onco.cc/companies/biodesix/), [BioInvent International](https://onco.cc/companies/bioinvent-international/), [Black Diamond Therapeutics](https://onco.cc/companies/black-diamond-therapeutics/), [Boehringer Ingelheim](https://onco.cc/companies/boehringer-ingelheim/), [BridgeBio Oncology Therapeutics](https://onco.cc/companies/bridgebio-oncology-therapeutics/), [Bristol Myers Squibb](https://onco.cc/companies/bms/), [Candel Therapeutics](https://onco.cc/companies/candel-therapeutics/), [CatalYm](https://onco.cc/companies/catalym/), [CellSight Technologies](https://onco.cc/companies/cellsight-technologies/), [Celltrion](https://onco.cc/companies/celltrion/), [Chinese Thoracic Oncology Group](https://onco.cc/companies/ctong/), [Chugai Pharmaceutical](https://onco.cc/companies/chugai/), [CivaTech Oncology](https://onco.cc/companies/civatech-oncology/), [Cofactor Genomics](https://onco.cc/companies/cofactor-genomics/), [Compass Therapeutics](https://onco.cc/companies/compass-therapeutics/), [D3 Bio (Wuxi)](https://onco.cc/companies/d3-bio-wuxi/), [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/), [DELFI Diagnostics](https://onco.cc/companies/delfi-diagnostics/), [Delta-Fly Pharma](https://onco.cc/companies/delta-fly-pharma/), [Dizal Pharmaceutical](https://onco.cc/companies/dizal/), [Eikon Therapeutics](https://onco.cc/companies/eikon-therapeutics/), [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/), [Ellipses Pharma](https://onco.cc/companies/ellipses-pharma/), [Elpiscience (Suzhou) Biopharma](https://onco.cc/companies/elpiscience-suzhou-biopharma/), [Enliven Therapeutics](https://onco.cc/companies/enliven-therapeutics/), [EpicentRx](https://onco.cc/companies/epicentrx/), [ETOP IBCSG Partners Foundation](https://onco.cc/companies/etop-ibcsg/), [Foghorn Therapeutics](https://onco.cc/companies/foghorn-therapeutics/), [Frontier Medicines](https://onco.cc/companies/frontier-medicines/), [Fujirebio](https://onco.cc/companies/fujirebio/), [Genelux](https://onco.cc/companies/genelux/), [Genprex](https://onco.cc/companies/genprex/), [GI Innovation](https://onco.cc/companies/gi-innovation/), [GTx](https://onco.cc/companies/gtx/), [GV20 Therapeutics](https://onco.cc/companies/gv20-therapeutics/), [Haihe Biopharma](https://onco.cc/companies/haihe-biopharma/), [Haystack Oncology](https://onco.cc/companies/haystack-oncology/), [Imagene AI](https://onco.cc/companies/imagene-ai/), [Immuneering](https://onco.cc/companies/immuneering/), [Immunovaccine (IMV)](https://onco.cc/companies/immunovaccine/), [Immutep](https://onco.cc/companies/immutep/), [Inivata](https://onco.cc/companies/inivata/), [Intergroupe Francophone de Cancérologie Thoracique](https://onco.cc/companies/ifct/), [InxMed](https://onco.cc/companies/inxmed/), [iOnctura](https://onco.cc/companies/ionctura/), [Ionis Pharmaceuticals](https://onco.cc/companies/ionis/), [Japan Clinical Oncology Group (JCOG)](https://onco.cc/companies/jcog/), [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/), [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/), [Kanvas Biosciences](https://onco.cc/companies/kanvas-biosciences/), [Korean Cancer Study Group](https://onco.cc/companies/kcsg/), [Krystal Biotech](https://onco.cc/companies/krystal-biotech/), [Kumquat Biosciences](https://onco.cc/companies/kumquat-biosciences/), [Lucence](https://onco.cc/companies/lucence/), [Lunit](https://onco.cc/companies/lunit/), [mAbxience Research S.L.](https://onco.cc/companies/mabxience-research-s-l/), [Maia Biotechnology](https://onco.cc/companies/maia-biotechnology/), [MBrace Therapeutics](https://onco.cc/companies/mbrace-therapeutics/), [Merck & Co. (MSD)](https://onco.cc/companies/merck/), [Merck KGaA (EMD Serono)](https://onco.cc/companies/merck-kgaa/), [Molecular Partners](https://onco.cc/companies/molecular-partners/), [Multitude Therapeutics](https://onco.cc/companies/multitude-therapeutics/), [Mythic Therapeutics](https://onco.cc/companies/mythic-therapeutics/), [Nanjing Leads Biolabs](https://onco.cc/companies/nanjing-leads-biolabs/), [Nerviano Medical Sciences](https://onco.cc/companies/nerviano-medical-sciences/), [Novartis](https://onco.cc/companies/novartis/), [Nucleix](https://onco.cc/companies/nucleix/), [Nuvalent](https://onco.cc/companies/nuvalent/), [Nuvation Bio](https://onco.cc/companies/nuvation-bio/), [Obsidian Therapeutics](https://onco.cc/companies/obsidian-therapeutics/), [On Target Laboratories](https://onco.cc/companies/on-target-laboratories/), [Onc.AI](https://onco.cc/companies/onc-ai/), [OncoC4](https://onco.cc/companies/oncoc4/), [OncoHost](https://onco.cc/companies/oncohost/), [Optellum](https://onco.cc/companies/optellum/), [ORIC Pharmaceuticals](https://onco.cc/companies/oric-pharmaceuticals/), [Orion, Orion Pharma](https://onco.cc/companies/orion-orion-pharma/), [OSE Immunotherapeutics](https://onco.cc/companies/ose-immunotherapeutics/), [Outcomes4Me](https://onco.cc/companies/outcomes4me/), [Owlstone Medical](https://onco.cc/companies/owlstone-medical/), [P-Cure](https://onco.cc/companies/p-cure/), [Pathos AI](https://onco.cc/companies/pathos-ai/), [Peregrine Pharmaceuticals (now Avid Bioservices)](https://onco.cc/companies/peregrine-avid/), [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/), [Proxygen](https://onco.cc/companies/proxygen/), [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/), [Radiopharm Theranostics](https://onco.cc/companies/radiopharm-theranostics/), [Roche / Genentech](https://onco.cc/companies/roche-genentech/), [Salubris Biotherapeutics](https://onco.cc/companies/salubris-biotherapeutics/), [Shanghai Fosun Pharmaceutical Industrial Development](https://onco.cc/companies/shanghai-fosun-pharmaceutical-industrial-development/), [Shanghai Juncell Therapeutics](https://onco.cc/companies/shanghai-juncell-therapeutics/), [Shenzhen Ionova Life Sciences](https://onco.cc/companies/shenzhen-ionova-life-sciences/), [Shenzhen TargetRx](https://onco.cc/companies/shenzhen-targetrx/), [Sinocelltech](https://onco.cc/companies/sinocelltech/), [Spectrum Pharmaceuticals](https://onco.cc/companies/spectrum-pharmaceuticals/), [STCube](https://onco.cc/companies/stcube/), [Strata Oncology](https://onco.cc/companies/strata-oncology/), [Summit Therapeutics](https://onco.cc/companies/summit-therapeutics/), [SunHo Biopharmaceutical](https://onco.cc/companies/sunho-biopharmaceutical/), [Suzhou BlueHorse Therapeutics](https://onco.cc/companies/suzhou-bluehorse-therapeutics/), [Tango Therapeutics](https://onco.cc/companies/tango-therapeutics/), [Telik](https://onco.cc/companies/telik/), [Transgene](https://onco.cc/companies/transgene/), [Triana Biomedicines](https://onco.cc/companies/triana-biomedicines/), [TROG Cancer Research](https://onco.cc/companies/trog/), [Tubulis (Gilead)](https://onco.cc/companies/tubulis/), [TYK Medicines](https://onco.cc/companies/tyk-medicines/), [Vergent Bioscience](https://onco.cc/companies/vergent-bioscience/), [VolitionRx](https://onco.cc/companies/volitionrx/), [Vyriad](https://onco.cc/companies/vyriad/), [Wayshine Biopharm](https://onco.cc/companies/wayshine-biopharm/), [West Japan Oncology Group](https://onco.cc/companies/wjog/), [XACT Robotics](https://onco.cc/companies/xact-robotics/), [Xcovery](https://onco.cc/companies/xcovery/), [Xilio Therapeutics](https://onco.cc/companies/xilio-therapeutics/), [Xuanzhu Biopharmaceutical](https://onco.cc/companies/xuanzhu-biopharmaceutical/), [Yuhan Corporation](https://onco.cc/companies/yuhan/)
- pathways: [Cancer cachexia](https://onco.cc/pathways/cachexia-biology/), [Epithelial-mesenchymal transition & drug efflux](https://onco.cc/pathways/emt/), [Field cancerisation](https://onco.cc/pathways/field-cancerisation/), [KEAP1-NRF2 antioxidant pathway](https://onco.cc/pathways/keap1-nrf2/), [Lineage plasticity & neuroendocrine transformation](https://onco.cc/pathways/lineage-plasticity-neuroendocrine/), [Non-small cell lung cancer (KEGG map)](https://onco.cc/pathways/nsclc-signalling/), [PD-1 / PD-L1 immune checkpoint & T-cell activation](https://onco.cc/pathways/pd1-checkpoint/), [PI3K / AKT / mTOR](https://onco.cc/pathways/pi3k-akt-mtor/), [RAS / RAF / MEK / ERK (MAPK)](https://onco.cc/pathways/ras-mapk/), [Receptor tyrosine kinase activation](https://onco.cc/pathways/rtk-activation/), [SWI/SNF chromatin remodelling](https://onco.cc/pathways/swi-snf-chromatin/), [The blood-brain barrier & brain metastasis](https://onco.cc/pathways/blood-brain-barrier-metastasis/), [VEGF angiogenesis](https://onco.cc/pathways/vegf-angiogenesis/)
- terms: [Adenocarcinoma](https://onco.cc/terms/adenocarcinoma/), [BRAF V600E mutation](https://onco.cc/terms/braf-v600-mutation/), [Brain metastases (intracranial disease)](https://onco.cc/terms/brain-metastases/), [Bronchoscopy (EBUS, robotic navigation)](https://onco.cc/terms/bronchoscopy/), [Cancer cachexia](https://onco.cc/terms/cachexia/), [Chemoradiation (chemoradiotherapy, CRT)](https://onco.cc/terms/chemoradiation/), [Clonal evolution and the ecological view of cancer](https://onco.cc/terms/clonal-evolution-theory/), [Consolidation therapy](https://onco.cc/terms/consolidation-therapy/), [Differentiation](https://onco.cc/terms/differentiation/), [EGFR C797S](https://onco.cc/terms/c797s/), [EGFR exon 19 deletion & L858R](https://onco.cc/terms/egfr-exon19-l858r/), [EGFR exon 20 insertion](https://onco.cc/terms/egfr-exon20-insertion/), [EGFR mutation subtypes (exon 19 deletion, L858R, exon 20 insertion, T790M)](https://onco.cc/terms/egfr-mutation-subtypes/), [HER2-positive (IHC 3+ or ISH-amplified)](https://onco.cc/terms/her2-positive/), [Histologic transformation](https://onco.cc/terms/histologic-transformation/), [Histology](https://onco.cc/terms/histology/), [Immune surveillance and cancer immunoediting](https://onco.cc/terms/immune-surveillance-immunoediting/), [KRAS mutation subtypes (G12C, G12D, G12V)](https://onco.cc/terms/kras-mutation-subtypes/), [Lobectomy](https://onco.cc/terms/lobectomy/), [Maintenance therapy](https://onco.cc/terms/maintenance-therapy/), [Malignant pleural effusion and ascites](https://onco.cc/terms/pleural-effusion/), [Mediastinum](https://onco.cc/terms/mediastinum/), [MET amplification (bypass resistance)](https://onco.cc/terms/met-amplification/), [MET exon 14 skipping mutation](https://onco.cc/terms/met-exon-14-skipping/), [Oligoprogression](https://onco.cc/terms/oligoprogression/), [Pleura](https://onco.cc/terms/pleura/), [Pleurodesis and indwelling pleural catheter](https://onco.cc/terms/pleurodesis/), [Pneumonectomy](https://onco.cc/terms/pneumonectomy/), [Radiation pneumonitis and lung fibrosis](https://onco.cc/terms/radiation-pneumonitis/), [Resectable, borderline resectable and unresectable](https://onco.cc/terms/resectability/), [Segmentectomy (sublobar resection)](https://onco.cc/terms/segmentectomy/), [Squamous cell carcinoma](https://onco.cc/terms/squamous-cell-carcinoma/), [STK11 / KEAP1 co-mutations](https://onco.cc/terms/stk11-keap1/), [Tumour proportion score (TPS)](https://onco.cc/terms/tps/), [Tumour-agnostic (tissue-agnostic) approval](https://onco.cc/terms/tumour-agnostic/)
- trials: [177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors](https://onco.cc/trials/nct07189871/), [A 2-part Phase 1/2 Open-label Trial on ODM-212](https://onco.cc/trials/nct07563738/), [A Beta-only IL-2 ImmunoTherapY Study](https://onco.cc/trials/nct05086692/), [A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)](https://onco.cc/trials/nct07190248/), [A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations](https://onco.cc/trials/nct06735391/), [A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)](https://onco.cc/trials/nct06698042/), [A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer](https://onco.cc/trials/nct05913089/), [A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients](https://onco.cc/trials/nct05787613/), [A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I ](https://onco.cc/trials/nct07513376/), [A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)](https://onco.cc/trials/nct07554339/), [A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality](https://onco.cc/trials/nct06496490/), [A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors](https://onco.cc/trials/nct06581419/), [A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced ](https://onco.cc/trials/nct07111520/), [A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)](https://onco.cc/trials/nct05989542/), [A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation](https://onco.cc/trials/nct07231068/), [A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07439094/), [A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations](https://onco.cc/trials/nct07629960/), [A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors](https://onco.cc/trials/nct04686682/), [A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07459751/), [A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct06868277/), [A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous N](https://onco.cc/trials/nct06627647/), [A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-s](https://onco.cc/trials/nct06692738/), [A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung](https://onco.cc/trials/nct05984277/), [A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC](https://onco.cc/trials/nct05211895/), [A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05221840/), [A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection](https://onco.cc/trials/nct05120349/), [A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors](https://onco.cc/trials/nct07636785/), [A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing ](https://onco.cc/trials/nct06956690/), [A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Sol](https://onco.cc/trials/nct06427941/), [A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC](https://onco.cc/trials/nct07491497/), [A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors](https://onco.cc/trials/nct07020221/), [A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC](https://onco.cc/trials/nct05394831/), [A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer](https://onco.cc/trials/nct04036682/), [A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946](https://onco.cc/trials/nct06616766/), [A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct05585320/), [A Phase 2 Clinical Study of ABSK061 and ABSK043](https://onco.cc/trials/nct06632262/), [A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib](https://onco.cc/trials/nct06668103/), [A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib](https://onco.cc/trials/nct07164170/), [A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)](https://onco.cc/trials/nct06593522/), [A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC](https://onco.cc/trials/nct06246110/), [A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC](https://onco.cc/trials/nct07562581/), [A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07659782/), [A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors](https://onco.cc/trials/nct06695845/), [A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation](https://onco.cc/trials/nct07174908/), [A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Ins](https://onco.cc/trials/nct07182682/), [A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer](https://onco.cc/trials/nct05902988/), [A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib](https://onco.cc/trials/nct07362940/), [A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies](https://onco.cc/trials/nct05123482/), [A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors](https://onco.cc/trials/nct06848699/), [A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC](https://onco.cc/trials/nct05543330/), [A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers](https://onco.cc/trials/nct05910827/), [A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer](https://onco.cc/trials/nct07253142/), [A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct06907615/), [A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)](https://onco.cc/trials/nct06295432/), [A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07489716/), [A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)](https://onco.cc/trials/nct06015503/), [A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07669779/), [A Phase II Study of GC101 in NSCLC](https://onco.cc/trials/nct07560111/), [A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Adv](https://onco.cc/trials/nct06962865/), [A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients](https://onco.cc/trials/nct07171606/), [A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC](https://onco.cc/trials/nct07269782/), [A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer](https://onco.cc/trials/nct07444437/), [A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients](https://onco.cc/trials/nct06564324/), [A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy](https://onco.cc/trials/nct05450692/), [A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients](https://onco.cc/trials/nct05870319/), [A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer（TAISHAN-302）](https://onco.cc/trials/nct06612151/), [A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer](https://onco.cc/trials/nct04951635/), [A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC](https://onco.cc/trials/nct06908304/), [A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following C](https://onco.cc/trials/nct06564844/), [A Phase IIII Study of AL8326 in Small Cell Lung Cancer](https://onco.cc/trials/nct06247605/), [A Platform Study in Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct06996782/), [A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer](https://onco.cc/trials/nct05565378/), [A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05654454/), [A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07365319/), [A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC](https://onco.cc/trials/nct05246514/), [A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-s](https://onco.cc/trials/nct07640789/), [A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU](https://onco.cc/trials/nct06382129/), [A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)](https://onco.cc/trials/nct06382116/), [A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC](https://onco.cc/trials/nct04606771/), [A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07217301/), [A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer](https://onco.cc/trials/nct04641754/), [A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors](https://onco.cc/trials/nct06244771/), [A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases](https://onco.cc/trials/nct06970639/), [A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants Wi](https://onco.cc/trials/nct05920356/), [A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Particip](https://onco.cc/trials/nct06793215/), [A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small C](https://onco.cc/trials/nct05170204/), [A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors](https://onco.cc/trials/nct05417321/), [A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Par](https://onco.cc/trials/nct05789082/), [A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)](https://onco.cc/trials/nct05526755/), [A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct05592626/), [A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene](https://onco.cc/trials/nct04395677/), [A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer](https://onco.cc/trials/nct02152631/), [A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)](https://onco.cc/trials/nct06875310/), [A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC](https://onco.cc/trials/nct06617416/), [A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07623356/), [A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct05488314/), [A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure](https://onco.cc/trials/nct04988295/), [A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07227025/), [A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct06667076/), [A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05498428/), [A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05047250/), [A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC](https://onco.cc/trials/nct04995523/), [A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct06472076/), [A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations](https://onco.cc/trials/nct06706076/), [A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung ](https://onco.cc/trials/nct05880706/), [A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU](https://onco.cc/trials/nct07642024/), [A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct06498986/), [A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metas](https://onco.cc/trials/nct06838273/), [A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and ](https://onco.cc/trials/nct06475300/), [A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors](https://onco.cc/trials/nct05949619/), [A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NS](https://onco.cc/trials/nct07264816/), [A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer](https://onco.cc/trials/nct06114511/), [A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC](https://onco.cc/trials/nct07178795/), [A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct04895709/), [A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)](https://onco.cc/trials/nct06345729/), [A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Ce](https://onco.cc/trials/nct06465329/), [A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions](https://onco.cc/trials/nct04538664/), [A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct05908734/), [A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)](https://onco.cc/trials/nct05460273/), [A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2](https://onco.cc/trials/nct06003231/), [A Study of DM005 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06515990/), [A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors](https://onco.cc/trials/nct04440735/), [A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients](https://onco.cc/trials/nct03706690/), [A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)](https://onco.cc/trials/nct05668988/), [A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies](https://onco.cc/trials/nct05443126/), [A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer](https://onco.cc/trials/nct06623136/), [A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer](https://onco.cc/trials/nct06119581/), [A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct07172802/), [A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies](https://onco.cc/trials/nct05669430/), [A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct06172478/), [A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06147570/), [A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06417008/), [A Study of IBI363 in Subjects with Advanced Solid Malignancies](https://onco.cc/trials/nct06281678/), [A Study of IDP-001 in Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct07602842/), [A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (](https://onco.cc/trials/nct06077760/), [A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)](https://onco.cc/trials/nct07221474/), [A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)](https://onco.cc/trials/nct06780085/), [A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China](https://onco.cc/trials/nct05009329/), [A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1](https://onco.cc/trials/nct05276726/), [A Study of JMT203 in Patients With Cancer Cachexia](https://onco.cc/trials/nct06868849/), [A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct06667908/), [A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)](https://onco.cc/trials/nct05388669/), [A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05297890/), [A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma](https://onco.cc/trials/nct05456256/), [A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer](https://onco.cc/trials/nct06954246/), [A Study of MT-4561 in Patients With Various Advanced Solid Tumors](https://onco.cc/trials/nct06943521/), [A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct04302025/), [A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)](https://onco.cc/trials/nct06855771/), [A Study of NDI 1150-101 in Patients With Solid Tumors](https://onco.cc/trials/nct05128487/), [A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC](https://onco.cc/trials/nct07586202/), [A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer](https://onco.cc/trials/nct04025879/), [A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer](https://onco.cc/trials/nct03800134/), [A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct07098338/), [A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents](https://onco.cc/trials/nct06090266/), [A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S](https://onco.cc/trials/nct04351555/), [A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrol](https://onco.cc/trials/nct06099782/), [A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)](https://onco.cc/trials/nct06623422/), [A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-34](https://onco.cc/trials/nct06731907/), [A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection](https://onco.cc/trials/nct05487391/), [A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer](https://onco.cc/trials/nct05690945/), [A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RE](https://onco.cc/trials/nct02411448/), [A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer](https://onco.cc/trials/nct04077099/), [A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)](https://onco.cc/trials/nct06140836/), [A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients](https://onco.cc/trials/nct06879717/), [A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRET](https://onco.cc/trials/nct03157128/), [A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct04819100/), [A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer](https://onco.cc/trials/nct06012435/), [A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC](https://onco.cc/trials/nct06754930/), [A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations](https://onco.cc/trials/nct06430437/), [A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC](https://onco.cc/trials/nct07183189/), [A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC](https://onco.cc/trials/nct06671379/), [A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06589778/), [A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer](https://onco.cc/trials/nct07229729/), [A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct05949606/), [A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other](https://onco.cc/trials/nct05956587/), [A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-](https://onco.cc/trials/nct05816252/), [A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advan](https://onco.cc/trials/nct06670196/), [A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative P](https://onco.cc/trials/nct06711900/), [A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06448312/), [A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct07622186/), [A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With](https://onco.cc/trials/nct06212752/), [A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With](https://onco.cc/trials/nct05722015/), [A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer](https://onco.cc/trials/nct02716116/), [A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05635708/), [A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations](https://onco.cc/trials/nct06644768/), [A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive](https://onco.cc/trials/nct06930794/), [A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07699328/), [A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct04996121/), [A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors](https://onco.cc/trials/nct07208773/), [A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer](https://onco.cc/trials/nct07739758/), [A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct07169994/), [A Study of YL202 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct07202364/), [A Study of YL202 in Selected Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06107686/), [A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)](https://onco.cc/trials/nct02912949/), [A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.](https://onco.cc/trials/nct05967689/), [A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)](https://onco.cc/trials/dllevate/), [A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07155187/), [A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult ](https://onco.cc/trials/nct06568939/), [A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07005102/), [A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Sm](https://onco.cc/trials/nct06312137/), [A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer](https://onco.cc/trials/nct06631989/), [A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer](https://onco.cc/trials/nct06868485/), [A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer](https://onco.cc/trials/nct04931654/), [A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pu](https://onco.cc/trials/nct07680764/), [A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection](https://onco.cc/trials/nct07128199/), [A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06311721/), [A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer](https://onco.cc/trials/nct06939595/), [A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell L](https://onco.cc/trials/nct06687369/), [A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation](https://onco.cc/trials/nct07566052/), [A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion](https://onco.cc/trials/nct07063745/), [A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS)](https://onco.cc/trials/nct06646276/), [A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases](https://onco.cc/trials/nct04603807/), [A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous N](https://onco.cc/trials/nct06561386/), [A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-s](https://onco.cc/trials/nct06348199/), [A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untr](https://onco.cc/trials/nct07005336/), [A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06984588/), [A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer](https://onco.cc/trials/nct07365241/), [A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct04765059/), [A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC](https://onco.cc/trials/nct06754644/), [A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation](https://onco.cc/trials/nct07668752/), [A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell](https://onco.cc/trials/nct07361497/), [A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC](https://onco.cc/trials/nct07206498/), [A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer](https://onco.cc/trials/nct05318573/), [A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Rese](https://onco.cc/trials/nct07541170/), [A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in N](https://onco.cc/trials/nct06829459/), [A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct03178552/), [A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC](https://onco.cc/trials/nct06010329/), [A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and P](https://onco.cc/trials/nct07361510/), [A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression](https://onco.cc/trials/nct06682793/), [A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression](https://onco.cc/trials/nct05736731/), [A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression](https://onco.cc/trials/nct06051695/), [A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07362459/), [A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advance](https://onco.cc/trials/nct07223047/), [A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations](https://onco.cc/trials/nct07610798/), [A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Pre](https://onco.cc/trials/nct06946797/), [A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors](https://onco.cc/trials/nct06747585/), [A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors](https://onco.cc/trials/nct07169734/), [A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07538804/), [A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy](https://onco.cc/trials/nct05941897/), [A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth](https://onco.cc/trials/nct05801029/), [A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other](https://onco.cc/trials/nct05081609/), [A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct07115043/), [A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small ](https://onco.cc/trials/nct06606847/), [A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer](https://onco.cc/trials/nct05361174/), [A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participan](https://onco.cc/trials/nct06417814/), [A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic N](https://onco.cc/trials/nct05048797/), [A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS](https://onco.cc/trials/nct06008093/), [A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies](https://onco.cc/trials/nct05473156/), [A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct07154290/), [A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nsclc-4/), [A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small](https://onco.cc/trials/nct05785767/), [A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-sma](https://onco.cc/trials/nct06452277/), [A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment](https://onco.cc/trials/nct07601048/), [A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer](https://onco.cc/trials/nct05482568/), [A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC](https://onco.cc/trials/nct04316364/), [A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct06512051/), [A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer ](https://onco.cc/trials/nct03390686/), [A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small ](https://onco.cc/trials/nct05557591/), [A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult ](https://onco.cc/trials/nct05800015/), [A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemoth](https://onco.cc/trials/nct06161441/), [ADAURA](https://onco.cc/trials/adaura/), [Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations](https://onco.cc/trials/nct06041776/), [Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer](https://onco.cc/trials/nct00576914/), [Adjuvant Vinorelbine Plus Cisplatin(NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer(NSCLC)](https://onco.cc/trials/nct01124253/), [AENEAS](https://onco.cc/trials/aeneas/), [Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)](https://onco.cc/trials/aurora/), [AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer](https://onco.cc/trials/nct05904379/), [AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05840016/), [AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC](https://onco.cc/trials/nct05247684/), [AK129 Combination Therapy for Advanced Solid Tumors](https://onco.cc/trials/nct06943820/), [ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)](https://onco.cc/trials/alchemist/), [ALEX](https://onco.cc/trials/alex/), [ALINA](https://onco.cc/trials/alina/), [ALKOVE-1](https://onco.cc/trials/alkove-1/), [Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients](https://onco.cc/trials/nct04616209/), [Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations](https://onco.cc/trials/nct04687241/), [ALTA](https://onco.cc/trials/alta/), [ALTA-1L](https://onco.cc/trials/alta-1l/), [ALTER 0303](https://onco.cc/trials/alter-0303/), [AMT-116 in Combination With AK112 in Patients With Lung Cancer](https://onco.cc/trials/nct07590531/), [An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06693336/), [An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors](https://onco.cc/trials/nct07371663/), [Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations](https://onco.cc/trials/nct07336732/), [Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metas](https://onco.cc/trials/nct05841472/), [ARCHER 1009: A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer](https://onco.cc/trials/nct01360554/), [ARCHER 1050](https://onco.cc/trials/nct01774721/), [ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer](https://onco.cc/trials/nct06498479/), [ASCEND-4](https://onco.cc/trials/nct01828099/), [ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC](https://onco.cc/trials/nct04143607/), [ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy](https://onco.cc/trials/nct07109531/), [Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral](https://onco.cc/trials/nct01933932/), [Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)](https://onco.cc/trials/nct03974022/), [Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer](https://onco.cc/trials/nct04270591/), [Atamparib in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct07374419/), [Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mut](https://onco.cc/trials/nct04923906/), [Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer](https://onco.cc/trials/nct04614103/), [Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangeme](https://onco.cc/trials/nct02568267/), [Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations](https://onco.cc/trials/nct04579380/), [Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab](https://onco.cc/trials/nct07486817/), [Beamion LUNG-1](https://onco.cc/trials/beamion-lung-1/), [Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment](https://onco.cc/trials/nct06151574/), [Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutati](https://onco.cc/trials/nct07195695/), [BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors](https://onco.cc/trials/nct06205706/), [Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets](https://onco.cc/trials/nct05317858/), [BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors](https://onco.cc/trials/nct05120271/), [CALGB 140503 (Alliance)](https://onco.cc/trials/calgb-140503/), [CameL](https://onco.cc/trials/camel/), [CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC](https://onco.cc/trials/nct04495153/), [CheckMate 227](https://onco.cc/trials/checkmate-227/), [CheckMate 816](https://onco.cc/trials/checkmate-816/), [CHISEL (TROG 09.02)](https://onco.cc/trials/chisel/), [CHRYSALIS](https://onco.cc/trials/chrysalis/), [Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06896890/), [Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1](https://onco.cc/trials/nct06767514/), [Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC](https://onco.cc/trials/nct05009836/), [Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In](https://onco.cc/trials/nct06745908/), [CodeBreaK 200](https://onco.cc/trials/codebreak-200/), [Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery](https://onco.cc/trials/nct00005838/), [Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation](https://onco.cc/trials/nct05609578/), [Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct04379635/), [CROWN](https://onco.cc/trials/crown/), [D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standar](https://onco.cc/trials/nct06300177/), [Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)](https://onco.cc/trials/nct05555732/), [DESTINY-Lung01](https://onco.cc/trials/destiny-lung01/), [DESTINY-Lung02](https://onco.cc/trials/destiny-lung02/), [Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors](https://onco.cc/trials/nct04140500/), [Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy](https://onco.cc/trials/nct05431270/), [Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas](https://onco.cc/trials/nct05751798/), [Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC](https://onco.cc/trials/nct07467863/), [Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC](https://onco.cc/trials/nct07641023/), [Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation](https://onco.cc/trials/nct03833154/), [DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)](https://onco.cc/trials/nct07070440/), [DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)](https://onco.cc/trials/nct06276283/), [Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL ](https://onco.cc/trials/nct06463665/), [Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer](https://onco.cc/trials/nct07276789/), [Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion](https://onco.cc/trials/nct05466149/), [Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors](https://onco.cc/trials/nct03485209/), [Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy](https://onco.cc/trials/nct04655976/), [EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study](https://onco.cc/trials/nct06486142/), [EMPOWER-Lung 1](https://onco.cc/trials/empower-lung-1/), [Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib](https://onco.cc/trials/nct06120140/), [eXalt3](https://onco.cc/trials/nct02767804/), [FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC](https://onco.cc/trials/nct06303505/), [Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation](https://onco.cc/trials/nct06956001/), [First in Human Study of TUB-030 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06657222/), [First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI](https://onco.cc/trials/nct05920135/), [First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations](https://onco.cc/trials/nct06043817/), [First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b](https://onco.cc/trials/nct03319628/), [FLAURA](https://onco.cc/trials/flaura/), [FLAURA2](https://onco.cc/trials/flaura2/), [FURLONG](https://onco.cc/trials/furlong/), [Gefitinib vs gefitinib plus pemetrexed-carboplatin in EGFR-mutant lung cancer (Tata Memorial)](https://onco.cc/trials/gefitinib-chemo-tmh/), [GEMSTONE-302](https://onco.cc/trials/gemstone-302/), [GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors](https://onco.cc/trials/nct04083599/), [GEOMETRY mono-1](https://onco.cc/trials/geometry-mono-1/), [GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors](https://onco.cc/trials/nct04977453/), [HARMONi-2](https://onco.cc/trials/harmoni-2/), [HARMONi-3](https://onco.cc/trials/harmoni-3/), [HARMONi-A](https://onco.cc/trials/harmoni-a/), [HC010 in First-line PD-L1 Positive Advanced NSCLC Patients](https://onco.cc/trials/nct07169552/), [HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer](https://onco.cc/trials/nct04619004/), [HERTHENA-Lung02](https://onco.cc/trials/herthena-lung02/), [IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small](https://onco.cc/trials/nct07122687/), [ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07452224/), [Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG](https://onco.cc/trials/nct06107374/), [IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC](https://onco.cc/trials/nct05994131/), [Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS](https://onco.cc/trials/nct05688280/), [Intratumoral N17350 in Advanced Solid Tumors](https://onco.cc/trials/nct07339176/), [IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)](https://onco.cc/trials/nct05742607/), [Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06928389/), [JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation](https://onco.cc/trials/nct06416410/), [JCOG0403](https://onco.cc/trials/jcog0403/), [JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations](https://onco.cc/trials/nct06391944/), [JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations](https://onco.cc/trials/nct06940401/), [KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)](https://onco.cc/trials/nct04165070/), [KEYNOTE-024 & KEYNOTE-189](https://onco.cc/trials/keynote-024-189/), [KEYNOTE-042](https://onco.cc/trials/keynote-042/), [KEYNOTE-407](https://onco.cc/trials/keynote-407/), [KEYNOTE-671](https://onco.cc/trials/keynote-671/), [Krascendo 1](https://onco.cc/trials/krascendo-1/), [KRYSTAL-12](https://onco.cc/trials/krystal-12/), [LAURA](https://onco.cc/trials/laura/), [LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib](https://onco.cc/trials/nct01828112/), [LIBRETTO-431](https://onco.cc/trials/libretto-431/), [Low-dose olanzapine for cancer anorexia (Tata Memorial)](https://onco.cc/trials/olanzapine-appetite-tmh/), [LUMINOSITY](https://onco.cc/trials/luminosity/), [LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC](https://onco.cc/trials/nct06216301/), [Lung-MAP (SWOG S1400 and S1900)](https://onco.cc/trials/lung-map/), [Lung-MAP S1400I: nivolumab with or without ipilimumab](https://onco.cc/trials/lung-map-s1400i/), [Lung-MAP S1800A: ramucirumab plus pembrolizumab](https://onco.cc/trials/lung-map-s1800a/), [MARIPOSA](https://onco.cc/trials/mariposa/), [MERMAID-1](https://onco.cc/trials/mermaid-1/), [MERMAID-2](https://onco.cc/trials/mermaid-2/), [MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)](https://onco.cc/trials/nct07431827/), [Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Lung Cancer Patients](https://onco.cc/trials/nct02802540/), [Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07150663/), [National Lung Matrix Trial](https://onco.cc/trials/national-lung-matrix-trial/), [Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC](https://onco.cc/trials/nct06765109/), [Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer](https://onco.cc/trials/nct07306624/), [Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer](https://onco.cc/trials/nct05116462/), [Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer](https://onco.cc/trials/nct05061550/), [Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients](https://onco.cc/trials/nct03916627/), [Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer](https://onco.cc/trials/nct05765877/), [NLST & NELSON (low-dose CT screening)](https://onco.cc/trials/nlst-nelson/), [Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study](https://onco.cc/trials/nct03381274/), [Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA](https://onco.cc/trials/nct03228277/), [ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors](https://onco.cc/trials/nct05671510/), [ORIENT-11](https://onco.cc/trials/orient-11/), [PACIFIC](https://onco.cc/trials/pacific/), [PACIFIC-2](https://onco.cc/trials/pacific-2/), [Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287](https://onco.cc/trials/nct06422143/), [Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors](https://onco.cc/trials/nct03647163/), [Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms](https://onco.cc/trials/nct05987956/), [Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)](https://onco.cc/trials/nct06430866/), [PHAROS](https://onco.cc/trials/pharos/), [Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combina](https://onco.cc/trials/nct04868877/), [Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients](https://onco.cc/trials/nct05074810/), [Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)](https://onco.cc/trials/nct05435248/), [Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations](https://onco.cc/trials/nct05256290/), [Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors](https://onco.cc/trials/nct07151040/), [Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer](https://onco.cc/trials/nct03907852/), [Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation](https://onco.cc/trials/nct05288205/), [Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.](https://onco.cc/trials/nct07148128/), [Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067](https://onco.cc/trials/nct04787042/), [Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct06162572/), [Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients](https://onco.cc/trials/nct05532696/), [Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)](https://onco.cc/trials/nct03944772/), [Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment](https://onco.cc/trials/nct05363280/), [Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G](https://onco.cc/trials/nct04613596/), [Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)](https://onco.cc/trials/nct07154706/), [Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor](https://onco.cc/trials/nct06105021/), [Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)](https://onco.cc/trials/nct04152499/), [Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors](https://onco.cc/trials/nct05024214/), [Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects](https://onco.cc/trials/nct07175220/), [Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung](https://onco.cc/trials/nct05195632/), [Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Facto](https://onco.cc/trials/nct07329322/), [Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung](https://onco.cc/trials/nct02485652/), [Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy](https://onco.cc/trials/nct02444819/), [Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy](https://onco.cc/trials/nct03334617/), [Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct02453282/), [Phase III Study of AK112 for NSCLC Patients](https://onco.cc/trials/nct06396065/), [Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Acti](https://onco.cc/trials/nct07291037/), [Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC](https://onco.cc/trials/nct06123754/), [Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Adva](https://onco.cc/trials/nct07170995/), [Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)](https://onco.cc/trials/fleteo/), [Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）](https://onco.cc/trials/nct06927986/), [Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell L](https://onco.cc/trials/nct06350097/), [Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations](https://onco.cc/trials/nct05687266/), [Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥](https://onco.cc/trials/nct06357533/), [Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07416994/), [Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation](https://onco.cc/trials/nct05358249/), [PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer](https://onco.cc/trials/nct06616532/), [Ponsegromab phase 2 in cancer cachexia](https://onco.cc/trials/ponsegromab-phase-2/), [Premedication to Reduce Amivantamab Associated Infusion Related Reactions](https://onco.cc/trials/nct05663866/), [Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib](https://onco.cc/trials/nct04486833/), [QUARTZ](https://onco.cc/trials/quartz/), [QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors](https://onco.cc/trials/nct03228667/), [RAPA-201 Therapy of Solid Tumors](https://onco.cc/trials/nct05144698/), [RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)](https://onco.cc/trials/sqnsclc/), [REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)](https://onco.cc/trials/nct05973773/), [Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other](https://onco.cc/trials/nct07468071/), [ROMANA 1 and ROMANA 2](https://onco.cc/trials/romana-1-2/), [RTOG 0617](https://onco.cc/trials/rtog-0617/), [SABR-COMET: stereotactic ablative radiotherapy for oligometastatic cancer](https://onco.cc/trials/sabr-comet/), [Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With P](https://onco.cc/trials/nct06170788/), [Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With](https://onco.cc/trials/nct06074588/), [Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, A](https://onco.cc/trials/nct06305754/), [Safety and Efficacy of OBX-115 in Advanced Solid Tumors](https://onco.cc/trials/nct06060613/), [Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer](https://onco.cc/trials/nct05117242/), [Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Che](https://onco.cc/trials/nct06841055/), [Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss](https://onco.cc/trials/nct06810544/), [Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer](https://onco.cc/trials/nct06712316/), [Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC](https://onco.cc/trials/nct03970746/), [Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC](https://onco.cc/trials/nct04140526/), [SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients](https://onco.cc/trials/nct04154956/), [Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment](https://onco.cc/trials/nct05261399/), [SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07662395/), [Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI](https://onco.cc/trials/nct07181499/), [SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations](https://onco.cc/trials/nct06080776/), [SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.](https://onco.cc/trials/nct05020457/), [SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct05020769/), [SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.](https://onco.cc/trials/nct05351788/), [SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07697586/), [SL-28 for Advanced Solid Tumours](https://onco.cc/trials/nct07341737/), [SOHO-01](https://onco.cc/trials/soho-01/), [SSGJ-707 in Advanced Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06980272/), [Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression](https://onco.cc/trials/nct04180371/), [Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies](https://onco.cc/trials/nct04561362/), [Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients](https://onco.cc/trials/nct04632758/), [Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer](https://onco.cc/trials/nct07189455/), [Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer](https://onco.cc/trials/nct04736173/), [Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recur](https://onco.cc/trials/nct03836352/), [Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)](https://onco.cc/trials/nct06710132/), [Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Ca](https://onco.cc/trials/nct05267626/), [Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies](https://onco.cc/trials/nct04644068/), [Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06706713/), [Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations](https://onco.cc/trials/nct06514027/), [Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC](https://onco.cc/trials/nct06569420/), [Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct07030257/), [Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)](https://onco.cc/trials/nct06881784/), [Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionab](https://onco.cc/trials/nct05215340/), [Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct05651022/), [Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).](https://onco.cc/trials/nct03164616/), [Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)](https://onco.cc/trials/nct03003962/), [Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)](https://onco.cc/trials/nct02542293/), [Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)](https://onco.cc/trials/nct03775486/), [Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.](https://onco.cc/trials/nct05445843/), [Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy ](https://onco.cc/trials/nct06726265/), [Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors](https://onco.cc/trials/nct06128551/), [Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs](https://onco.cc/trials/nct06567015/), [Study of GV20-0251 in Participants With Solid Tumor Malignancies](https://onco.cc/trials/nct07070518/), [Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalen](https://onco.cc/trials/nct04198766/), [Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer](https://onco.cc/trials/nct05403385/), [Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy](https://onco.cc/trials/nct07100080/), [Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer](https://onco.cc/trials/nct05132075/), [Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation](https://onco.cc/trials/nct04699188/), [Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer](https://onco.cc/trials/nct05620134/), [Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS](https://onco.cc/trials/nct06895031/), [Study of LP-184 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct05933265/), [Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)](https://onco.cc/trials/nct04956640/), [Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors](https://onco.cc/trials/nct04930432/), [Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation](https://onco.cc/trials/nct05737706/), [Study of NEO-201 in Solid Tumors Expansion Cohorts](https://onco.cc/trials/nct03476681/), [Study of Novel Treatment Combinations in Patients With Lung Cancer](https://onco.cc/trials/nct05633667/), [Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06890598/), [Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)](https://onco.cc/trials/nct07079475/), [Study of Oral MRT-2359 in Selected Cancer Patients](https://onco.cc/trials/nct05546268/), [Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)](https://onco.cc/trials/nct05609968/), [Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan](https://onco.cc/trials/nct04956692/), [Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mu](https://onco.cc/trials/nct07777822/), [Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)](https://onco.cc/trials/nct04380636/), [Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC](https://onco.cc/trials/nct04786964/), [Study of PF-07248144 in Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct04606446/), [Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors](https://onco.cc/trials/nct07397338/), [Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC](https://onco.cc/trials/nct06162221/), [Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities](https://onco.cc/trials/nct04683250/), [Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS](https://onco.cc/trials/nct05379985/), [Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors](https://onco.cc/trials/nct06040541/), [Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer](https://onco.cc/trials/nct03937154/), [Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)](https://onco.cc/trials/nct03767348/), [Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct05089734/), [Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct05186974/), [Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers](https://onco.cc/trials/nct05098132/), [Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas](https://onco.cc/trials/nct05565417/), [Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors](https://onco.cc/trials/nct05887492/), [Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer](https://onco.cc/trials/nct06899126/), [Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06903377/), [Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct05985655/), [Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D,](https://onco.cc/trials/nct05925530/), [Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [](https://onco.cc/trials/nct02486718/), [Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm](https://onco.cc/trials/nct05546866/), [Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer](https://onco.cc/trials/nct07288177/), [Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With](https://onco.cc/trials/nct05607550/), [Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations](https://onco.cc/trials/nct06772623/), [Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nsclc-2/), [Study to Evaluate D-1553 in Subjects With Solid Tumors](https://onco.cc/trials/nct04585035/), [Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants W](https://onco.cc/trials/nct07185997/), [Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct05168566/), [Study With Various Immunotherapy Treatments in Participants With Lung Cancer](https://onco.cc/trials/nct05676931/), [Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)](https://onco.cc/trials/nct05712902/), [Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer](https://onco.cc/trials/symbiotic-lung-01/), [Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer](https://onco.cc/trials/symbiotic-lung-04/), [Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC](https://onco.cc/trials/nct07489066/), [Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers](https://onco.cc/trials/nct07227298/), [Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients](https://onco.cc/trials/nct02579564/), [TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations](https://onco.cc/trials/nct04129502/), [Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC](https://onco.cc/trials/nct04919811/), [TAPUR (Targeted Agent and Profiling Utilization Registry)](https://onco.cc/trials/tapur/), [TeliMET NSCLC-01](https://onco.cc/trials/telimet-nsclc-01/), [Test-retest Evaluation of [18F]F-AraG PET](https://onco.cc/trials/nct06084806/), [TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct05955391/), [TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nsclc-3/), [THIO Sequenced With Cemiplimab in Advanced NSCLC](https://onco.cc/trials/nct05208944/), [This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lu](https://onco.cc/trials/nct06758401/), [To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy](https://onco.cc/trials/nct04853342/), [To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic N](https://onco.cc/trials/nct05442060/), [Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC](https://onco.cc/trials/nct07246863/), [Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC](https://onco.cc/trials/nct07098988/), [Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor](https://onco.cc/trials/nct06472245/), [Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)](https://onco.cc/trials/nct06635824/), [TROPION-Lung01](https://onco.cc/trials/tropion-lung01/), [TROPION-Lung05](https://onco.cc/trials/tropion-lung05/), [TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma](https://onco.cc/trials/nct04969315/), [Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC](https://onco.cc/trials/nct04524689/), [TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases](https://onco.cc/trials/nct05948813/), [Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.](https://onco.cc/trials/nct06574347/), [Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI](https://onco.cc/trials/nct06343064/), [VISION (tepotinib)](https://onco.cc/trials/nct02864992/), [VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma](https://onco.cc/trials/nct03556228/), [Volrustomig Priming Regimens Exploratory Phase II Platform Study](https://onco.cc/trials/nct06448754/), [Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct06933329/), [Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05502237/)
- journals: [Clinical lung cancer](https://onco.cc/journals/clinical-lung-cancer/), [Journal of Thoracic Oncology](https://onco.cc/journals/journal-of-thoracic-oncology/), [Lung cancer](https://onco.cc/journals/lung-cancer-journal/), [Thoracic cancer](https://onco.cc/journals/thoracic-cancer/), [Zhongguo fei ai za zhi](https://onco.cc/journals/chinese-journal-of-lung-cancer/)
- institutions: [Aichi Cancer Center](https://onco.cc/institutions/aichi-cancer-center/), [Apollo Hospitals (Apollo Cancer Centres)](https://onco.cc/institutions/apollo-hospitals/), [Auckland City Hospital / Te Pūriri o Te Ora Cancer and Blood Service](https://onco.cc/institutions/auckland-city-hospital/), [Barts Cancer Institute / Barts Health NHS Trust](https://onco.cc/institutions/barts-cancer-institute/), [Cancer Center Clínica Universidad de Navarra / CIMA](https://onco.cc/institutions/cun-navarra/), [Cancer Council Australia](https://onco.cc/institutions/cancer-council-australia/), [Cancer Grand Challenges](https://onco.cc/institutions/cancer-grand-challenges/), [Cancer Research UK Manchester Institute](https://onco.cc/institutions/cruk-manchester-institute/), [Centre hospitalier de l'Université de Montréal (CHUM)](https://onco.cc/institutions/chum/), [Centro Nacional de Investigaciones Oncológicas (CNIO)](https://onco.cc/institutions/cnio/), [Chang Gung Memorial Hospital](https://onco.cc/institutions/chang-gung-memorial-hospital/), [Chinese Society of Clinical Oncology](https://onco.cc/institutions/csco/), [Dana-Farber Brigham Cancer Center](https://onco.cc/institutions/dana-farber/), [Erasmus MC Cancer Institute](https://onco.cc/institutions/erasmus-mc/), [Guangdong Provincial People's Hospital](https://onco.cc/institutions/guangdong-provincial-peoples-hospital/), [Harold C. Simmons Comprehensive Cancer Center, UT Southwestern](https://onco.cc/institutions/utsw-simmons/), [HealthCare Global Enterprises](https://onco.cc/institutions/hcg/), [Henan Cancer Hospital](https://onco.cc/institutions/henan-cancer-hospital/), [Hokkaido University Hospital](https://onco.cc/institutions/hokkaido-university-hospital/), [Hospital Universitario 12 de Octubre](https://onco.cc/institutions/12-de-octubre/), [Hunan Cancer Hospital](https://onco.cc/institutions/hunan-cancer-hospital/), [Inselspital, Bern University Hospital / University Cancer Center Inselspital](https://onco.cc/institutions/inselspital-bern/), [Instituto Alexander Fleming](https://onco.cc/institutions/instituto-alexander-fleming/), [Instituto Nacional de Câncer (INCA)](https://onco.cc/institutions/inca-brazil/), [Instituto Nacional de Cancerología (Mexico)](https://onco.cc/institutions/incan-mexico/), [Instituto Nacional de Oncología y Radiobiología (INOR)](https://onco.cc/institutions/inor-cuba/), [International Association for the Study of Lung Cancer](https://onco.cc/institutions/iaslc/), [IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola](https://onco.cc/institutions/sant-orsola-bologna/), [IRCCS Humanitas Research Hospital](https://onco.cc/institutions/humanitas/), [IRCCS Regina Elena National Cancer Institute](https://onco.cc/institutions/regina-elena-rome/), [Istanbul University Institute of Oncology](https://onco.cc/institutions/istanbul-oncology-institute/), [Istituto Nazionale Tumori IRCCS Fondazione G. Pascale](https://onco.cc/institutions/pascale-naples/), [Jiangsu Cancer Hospital](https://onco.cc/institutions/jiangsu-cancer-hospital/), [King Hussein Cancer Center](https://onco.cc/institutions/khcc/), [Koo Foundation Sun Yat-Sen Cancer Center](https://onco.cc/institutions/koo-foundation-sun-yat-sen-cancer-center/), [Kyoto University Hospital](https://onco.cc/institutions/kyoto-university-hospital/), [Kyushu University Hospital](https://onco.cc/institutions/kyushu-university-hospital/), [Laura and Isaac Perlmutter Cancer Center at NYU Langone Health](https://onco.cc/institutions/nyu-perlmutter/), [Lausanne University Hospital (CHUV) / Ludwig Institute Lausanne](https://onco.cc/institutions/chuv-lausanne/), [Leicester Cancer Research Centre / University Hospitals of Leicester](https://onco.cc/institutions/leicester-cancer-research-centre/), [LungenClinic Grosshansdorf](https://onco.cc/institutions/lungenclinic-grosshansdorf/), [Maria Skłodowska-Curie National Research Institute of Oncology](https://onco.cc/institutions/nio-warsaw/), [Markey Cancer Center, University of Kentucky](https://onco.cc/institutions/kentucky-markey/), [Max Healthcare (Max Institute of Cancer Care)](https://onco.cc/institutions/max-healthcare/), [MUSC Hollings Cancer Center](https://onco.cc/institutions/musc-hollings/), [National Cancer Center Hospital East](https://onco.cc/institutions/ncc-hospital-east/), [National Cancer Center Korea](https://onco.cc/institutions/ncc-korea/), [National Cancer Centre Singapore](https://onco.cc/institutions/nccs/), [National Cancer Registry Programme (ICMR-NINE, Bengaluru)](https://onco.cc/institutions/icmr-ncrp/), [National Taiwan University Hospital](https://onco.cc/institutions/ntuh/), [National University Hospital / National University Cancer Institute, Singapore](https://onco.cc/institutions/nuh-ncis/), [Osaka International Cancer Institute](https://onco.cc/institutions/osaka-international-cancer-institute/), [Prince of Wales Hospital / Chinese University of Hong Kong](https://onco.cc/institutions/prince-of-wales-hospital-cuhk/), [Queen Mary Hospital / University of Hong Kong](https://onco.cc/institutions/queen-mary-hospital-hku/), [Rajiv Gandhi Cancer Institute and Research Centre](https://onco.cc/institutions/rgci/), [Rigshospitalet, Copenhagen University Hospital](https://onco.cc/institutions/rigshospitalet/), [Seoul National University Hospital](https://onco.cc/institutions/snuh/), [Shandong Cancer Hospital and Institute](https://onco.cc/institutions/shandong-cancer-hospital/), [Shanghai Chest Hospital](https://onco.cc/institutions/shanghai-chest-hospital/), [Shanghai Pulmonary Hospital](https://onco.cc/institutions/shanghai-pulmonary-hospital/), [Shizuoka Cancer Center](https://onco.cc/institutions/shizuoka-cancer-center/), [Stand Up To Cancer](https://onco.cc/institutions/stand-up-to-cancer/), [Taipei Veterans General Hospital](https://onco.cc/institutions/taipei-veterans-general-hospital/), [The Francis Crick Institute](https://onco.cc/institutions/francis-crick/), [Tohoku University Hospital](https://onco.cc/institutions/tohoku-university-hospital/), [UC Davis Comprehensive Cancer Center](https://onco.cc/institutions/uc-davis-cancer/), [Uniklinik Köln (CIO)](https://onco.cc/institutions/uniklinik-koeln/), [Union Hospital, Tongji Medical College](https://onco.cc/institutions/union-hospital-wuhan/), [University College London Hospitals / UCL Cancer Institute](https://onco.cc/institutions/uclh/), [University Hospital Basel / Tumour Centre](https://onco.cc/institutions/usb-basel/), [University Hospital Southampton / Centre for Cancer Immunology](https://onco.cc/institutions/southampton-cancer/), [University Hospital Zurich / Comprehensive Cancer Center Zurich](https://onco.cc/institutions/usz-zurich/), [University of Colorado Cancer Center](https://onco.cc/institutions/colorado-cancer-center/), [University of Hawai'i Cancer Center](https://onco.cc/institutions/hawaii-cancer-center/), [Vanderbilt-Ingram Cancer Center](https://onco.cc/institutions/vanderbilt-ingram/), [VCU Massey Comprehensive Cancer Center](https://onco.cc/institutions/vcu-massey/), [Velindre Cancer Centre](https://onco.cc/institutions/velindre-cardiff/), [Vietnam National Cancer Hospital (K Hospital)](https://onco.cc/institutions/k-hospital-hanoi/), [Winship Cancer Institute of Emory University](https://onco.cc/institutions/emory-winship/), [Yale Cancer Center / Smilow Cancer Hospital](https://onco.cc/institutions/yale-cancer-center/), [Zhejiang Cancer Hospital](https://onco.cc/institutions/zhejiang-cancer-hospital/)
- ideas: [A cheap old tablet to restore appetite](https://onco.cc/ideas/idea-bio2-low-dose-olanzapine-appetite/), [A clone report from blood at every treatment cycle](https://onco.cc/ideas/idea-bio1-ctdna-clone-report/), [A coordinated FLASH radiotherapy evidence programme with shared dose-rate standards](https://onco.cc/ideas/idea-fund-flash-evidence-programme/), [A delivery-science moonshot for prevention we already own](https://onco.cc/ideas/idea-fund-prevention-moonshot/), [A standard platform to get drugs into the brain: focused ultrasound plus shuttle-engineered therapeutics](https://onco.cc/ideas/idea-moon-brain-delivery-platform/), [A standing platform for testing new drugs with radiotherapy](https://onco.cc/ideas/idea-tr2-rt-drug-platform/), [A test to tell true oligometastatic disease from hidden widespread spread](https://onco.cc/ideas/idea-bio2-oligometastatic-signature/), [Add a drug when the blood test turns, without stopping the one that works](https://onco.cc/ideas/idea-bio1-molecular-progression-add-on/), [Add the second drug on day one when the escape route is predictable](https://onco.cc/ideas/idea-bio1-upfront-bypass-combination/), [AI clears the normal lung screening scans so radiologists read only the suspicious ones](https://onco.cc/ideas/idea-prev-ldct-ai-negative-triage/), [AI malignancy scores to end repeat scans and biopsies for benign lung nodules](https://onco.cc/ideas/idea-prev-lung-nodule-ai-discharge/), [Automatic palliative care referral triggered by diagnosis, not by decline](https://onco.cc/ideas/idea-acc-automatic-early-palliative-triggers/), [Autonomous closed-loop adaptive therapy driven by blood tests and evolutionary models](https://onco.cc/ideas/idea-moon-closed-loop-adaptive-therapy/), [Bank three spatially separate tumour blocks from every resection](https://onco.cc/ideas/idea-bio1-multiregion-blocks-default/), [Biopsy the one lesion that is growing while the others shrink](https://onco.cc/ideas/idea-bio1-outlier-lesion-biopsy/), [Block the complement signal that recruits tumour-protecting cells](https://onco.cc/ideas/idea-bio2-complement-c5ar-blockade/), [Blunt the inflammation that wakes sleeping cancer cells](https://onco.cc/ideas/idea-bio2-il1-awakening-blockade/), [Borrow from past control arms to shrink the control group in phase 3](https://onco.cc/ideas/idea-tr1-bayesian-borrowing-smaller-controls/), [Brain metastases included by default in every solid-tumour trial](https://onco.cc/ideas/idea-tr1-brain-mets-default-included/), [Build a human model of the barrier that guards the brain fluid](https://onco.cc/ideas/idea-bio2-blood-csf-barrier-model/), [Burden-weighted portfolio targets for every major cancer funder](https://onco.cc/ideas/idea-fund-burden-weighted-portfolio/), [Capture diet, fibre and antibiotic exposure in every immunotherapy pivotal trial](https://onco.cc/ideas/idea-nl-diet-covariates-io-trials/), [Catch wasting early with a smart scale and a step counter](https://onco.cc/ideas/idea-bio2-remote-weight-step-monitoring/), [CD8 PET to stop or switch immunotherapy early](https://onco.cc/ideas/idea-cd8-pet-io/), [Combine the new anti-wasting antibody with exercise and protein](https://onco.cc/ideas/idea-bio2-gdf15-plus-exercise/), [Competing sponsors share one control arm in the same indication](https://onco.cc/ideas/idea-tr1-shared-control-arms-across-sponsors/), [Confirm low-dose olanzapine for appetite and weight in advanced cancer worldwide](https://onco.cc/ideas/idea-reg-olanzapine-cachexia-global-confirmation/), [Confirm or refute the harm of antioxidant supplements during chemotherapy](https://onco.cc/ideas/idea-nl-antioxidant-supplement-harm-confirmation/), [Confirm ultra-low-dose immunotherapy so it can be afforded where most patients live](https://onco.cc/ideas/idea-tr1-low-dose-immunotherapy-for-lmic/), [ctDNA-guided dose holidays for lung cancer targeted therapy](https://onco.cc/ideas/idea-bio1-ctdna-adaptive-tki/), [Dedicated cohorts for patients with performance status 2 in first-line trials](https://onco.cc/ideas/idea-tr1-ecog-2-dedicated-cohorts/), [Detect tumours changing cell type from RNA in the blood](https://onco.cc/ideas/idea-bio1-cfrna-plasticity-tracking/), [Evaluate clean-air policies using lung cancer in never-smokers](https://onco.cc/ideas/idea-prev-clean-air-never-smoker-endpoints/), [Every lung screening visit includes stop-smoking medicine, opt-out](https://onco.cc/ideas/idea-prev-opt-out-cessation-in-lung-screening/), [Every routine CT scan checked by AI for early cancer signs, with a tracked follow-up pathway](https://onco.cc/ideas/idea-prev-opportunistic-ct-ai-registry/), [Extended-interval immunotherapy: give checkpoint inhibitors every 8-12 weeks once stable](https://onco.cc/ideas/idea-tr1-extended-interval-checkpoint-dosing/), [Get the one approved appetite drug licensed beyond a single country](https://onco.cc/ideas/idea-bio2-anamorelin-access/), [Give immunotherapy in the morning](https://onco.cc/ideas/idea-chronotherapy-immunotherapy/), [Intercept cancer at the field stage](https://onco.cc/ideas/idea-field-interception/), [Kill drug-tolerant persisters through ferroptosis](https://onco.cc/ideas/idea-ferroptosis-persisters/), [Look for the resistant sub-population before the first dose](https://onco.cc/ideas/idea-bio1-baseline-ultradeep-resistant-clones/), [Lung screening eligibility by risk score, not pack-years, including high-risk never-smokers](https://onco.cc/ideas/idea-prev-lung-screening-risk-model-eligibility/), [Make bespoke mouse cancer models in weeks with in vivo gene editing](https://onco.cc/ideas/idea-bio1-somatic-crispr-gemms/), [Make cigarettes non-addictive by capping their nicotine](https://onco.cc/ideas/idea-prev-very-low-nicotine-mandate/), [Mandatory radon testing when homes are sold, with subsidised mitigation](https://onco.cc/ideas/idea-prev-radon-testing-at-property-sale/), [Map metabolic dependencies in the patient, not the dish](https://onco.cc/ideas/idea-metabolic-vulnerability-mapping/), [Microbiome transplant as a routine immunotherapy adjunct](https://onco.cc/ideas/idea-microbiome-io-fmt/), [Molecular indolence classifiers bundled with every screening programme](https://onco.cc/ideas/idea-moon-indolence-classifiers-with-screening/), [Pathologists order genomic profiling automatically at diagnosis of advanced cancer](https://onco.cc/ideas/idea-acc-reflex-genomic-profiling-at-diagnosis/), [Pause a failed drug so the tumour becomes sensitive to it again](https://onco.cc/ideas/idea-bio1-drug-holiday-resensitisation/), [Pre-surgery platform trials that test combinations on pathological response in months](https://onco.cc/ideas/idea-tr2-neoadjuvant-combo-platform/), [Prevention trials aimed only at brain metastasis](https://onco.cc/ideas/idea-bio2-brain-met-prevention-trials/), [Protect hearing from cisplatin in adults as we now do in children](https://onco.cc/ideas/idea-moon-hearing-protection-cisplatin/), [Protect the gut flora of patients about to start immunotherapy](https://onco.cc/ideas/idea-bio2-antibiotic-stewardship-io/), [Put cytisine, a cheap plant-based quit-smoking pill, on every essential medicines list](https://onco.cc/ideas/idea-prev-cytisine-essential-medicine/), [Randomise a cheap antihistamine alongside immunotherapy](https://onco.cc/ideas/idea-reg-antihistamine-plus-io-trial/), [Randomised trials of stopping immunotherapy after one year versus continuing](https://onco.cc/ideas/idea-tr1-immunotherapy-stop-trials/), [Re-test the metastasis, not the old primary, before every change of treatment](https://onco.cc/ideas/idea-bio1-rebiopsy-before-switch/), [Select cachexia trial patients by the hormone driving their wasting](https://onco.cc/ideas/idea-bio2-gdf15-stratified-enrolment/), [Select patients for cell therapy by whether their tumour holds reactive T cells](https://onco.cc/ideas/idea-bio2-til-reactivity-selection/), [Slow the tumour's mutation engine with APOBEC inhibitors during targeted therapy](https://onco.cc/ideas/idea-bio1-apobec-inhibitor-adjunct/), [Smoke-free generation laws with a built-in evaluation across countries](https://onco.cc/ideas/idea-prev-smokefree-generation-evaluation/), [Social impact bonds for cancer prevention, repaid from avoided treatment costs](https://onco.cc/ideas/idea-fund-social-impact-bonds-prevention/), [Standing reflex biomarker panels per tumour type, run without an oncologist's order](https://onco.cc/ideas/idea-acc-reflex-biomarker-panels-by-tumour/), [Switch drugs at maximum response, not at relapse](https://onco.cc/ideas/idea-bio1-first-strike-second-strike/), [Take lung screening scanners to supermarket car parks in the poorest areas](https://onco.cc/ideas/idea-prev-mobile-lung-screening-deprived-areas/), [Test a high-fibre diet as an immunotherapy adjunct](https://onco.cc/ideas/idea-bio2-fibre-diet-io-trial/), [Test alternating drug schedules against giving both drugs at once](https://onco.cc/ideas/idea-tr2-alternating-vs-concurrent/), [Test intermittent dosing of targeted drugs to delay resistance, with honest priors](https://onco.cc/ideas/idea-tr1-intermittent-dosing-to-delay-resistance/), [Test protein and resistance training during immunotherapy](https://onco.cc/ideas/idea-bio2-protein-plus-training-during-io/), [Treat brain metastases as a disease with its own trials programme](https://onco.cc/ideas/idea-fund-brain-metastases-programme/), [Treat cachexia as a disease: GDF-15 blockade plus anabolic and nutrition bundles](https://onco.cc/ideas/idea-moon-cachexia-as-treatable-disease/), [Treat cachexia before it starts](https://onco.cc/ideas/idea-cachexia-gdf15-prevention/), [Treat immunotherapy side-effects without wiping out the response](https://onco.cc/ideas/idea-bio2-steroid-sparing-irae/), [TROP2 PET to choose and sequence TROP2 ADCs](https://onco.cc/ideas/idea-trop2-pet-selection/), [Turn a brake back on: drugs that reactivate the PP2A phosphatase](https://onco.cc/ideas/idea-bio1-pp2a-activators/), [Unmask hidden antigens with a short epigenetic course before immunotherapy](https://onco.cc/ideas/idea-bio2-epigenetic-priming-cold-tumours/), [Use a blood test at six weeks to decide whether to keep going](https://onco.cc/ideas/idea-bio2-ctdna-six-week-io-switch/), [Use a hypoxia scan to pick patients for adenosine-pathway drugs](https://onco.cc/ideas/idea-bio2-hypoxia-guided-adenosine/), [Use LET, RBE and alpha/beta to decide when protons beat IMRT](https://onco.cc/ideas/idea-bio2-let-rbe-ab-selects-protons/), [Use the brain's own transport door to carry antibody drugs across](https://onco.cc/ideas/idea-bio2-transferrin-shuttle-adc/), [Use tumour DNA in blood to decide when to pause treatment in metastatic cancer](https://onco.cc/ideas/idea-tr1-ctdna-guided-stop-in-metastatic-disease/), [Video palliative care as an equivalent default option for patients far from a team](https://onco.cc/ideas/idea-acc-tele-palliative-care-default/), [Watch the immune system's response in the blood three weeks in](https://onco.cc/ideas/idea-bio2-tcr-repertoire-early-readout/)
- people: [Alexander Drilon](https://onco.cc/people/alexander-drilon/), [Alexis Cortot](https://onco.cc/people/alexis-cortot/), [Alfredo Addeo](https://onco.cc/people/alfredo-addeo/), [Alice T. Shaw](https://onco.cc/people/alice-shaw/), [Anne C. Chiang](https://onco.cc/people/anne-chiang/), [Ash A. Alizadeh](https://onco.cc/people/ash-alizadeh/), [Benjamin Besse](https://onco.cc/people/benjamin-besse/), [Benjamin Solomon](https://onco.cc/people/solomon-benjamin/), [Bob T. Li](https://onco.cc/people/bob-li/), [Byoung Chul Cho](https://onco.cc/people/cho-byoung-chul/), [C. S. Pramesh](https://onco.cc/people/pramesh-c-s/), [Caicun Zhou](https://onco.cc/people/zhou-caicun/), [Charles B. Simone II](https://onco.cc/people/charles-simone/), [Charles Swanton](https://onco.cc/people/charles-swanton/), [Charu Aggarwal](https://onco.cc/people/charu-aggarwal/), [Corinne Faivre-Finn](https://onco.cc/people/corinne-faivre-finn/), [D. Ross Camidge](https://onco.cc/people/ross-camidge/), [Dae Ho Lee](https://onco.cc/people/lee-dae-ho/), [Daniel A. Haber](https://onco.cc/people/daniel-haber/), [David Planchard](https://onco.cc/people/david-planchard/), [Denise R. Aberle](https://onco.cc/people/denise-aberle/), [Dong-Wan Kim](https://onco.cc/people/kim-dong-wan/), [Dongsheng Tu](https://onco.cc/people/tu-dongsheng/), [Enriqueta Felip](https://onco.cc/people/enriqueta-felip/), [Eric B. Haura](https://onco.cc/people/eric-haura/), [Everett E. Vokes](https://onco.cc/people/everett-vokes/), [Fabrice Barlesi](https://onco.cc/people/fabrice-barlesi/), [Ferdinandos Skoulidis](https://onco.cc/people/ferdinandos-skoulidis/), [Fiona Blackhall](https://onco.cc/people/fiona-blackhall/), [Frank McCormick](https://onco.cc/people/frank-mccormick/), [Gregory J. Riely](https://onco.cc/people/gregory-riely/), [Harry J. de Koning](https://onco.cc/people/harry-de-koning/), [Haruhiko Fukuda](https://onco.cc/people/fukuda-haruhiko/), [Heather A. Wakelee](https://onco.cc/people/heather-wakelee/), [Helena A. Yu](https://onco.cc/people/helena-yu/), [Hidetoshi Hayashi](https://onco.cc/people/hidetoshi-hayashi/), [Hye Ryun Kim](https://onco.cc/people/kim-hye-ryun/), [Jean-Charles Soria](https://onco.cc/people/jean-charles-soria/), [Jeffrey D. Bradley](https://onco.cc/people/jeffrey-bradley/), [Jennifer S. Temel](https://onco.cc/people/jennifer-temel/), [Jie He](https://onco.cc/people/he-jie/), [Jie Wang](https://onco.cc/people/wang-jie-cams/), [Jin Seok Ahn](https://onco.cc/people/jin-seok-ahn/), [Joe Y. Chang](https://onco.cc/people/joe-chang/), [John V. Heymach](https://onco.cc/people/john-heymach/), [Jonathan Spicer](https://onco.cc/people/jonathan-spicer/), [Julie R. Brahmer](https://onco.cc/people/julie-brahmer/), [Jürgen Wolf](https://onco.cc/people/juergen-wolf/), [Justin F. Gainor](https://onco.cc/people/justin-gainor/), [Karen Kelly](https://onco.cc/people/karen-kelly/), [Karim Vermaelen](https://onco.cc/people/karim-vermaelen/), [Kathy S. Albain](https://onco.cc/people/kathy-albain/), [Keunchil Park](https://onco.cc/people/keunchil-park/), [Kevan M. Shokat](https://onco.cc/people/kevan-shokat/), [Koichi Goto](https://onco.cc/people/goto-koichi/), [Kumar Prabhash](https://onco.cc/people/prabhash-kumar/), [Lecia V. Sequist](https://onco.cc/people/lecia-sequist/), [Li Zhang](https://onco.cc/people/zhang-li-sysucc/), [Luis Paz-Ares](https://onco.cc/people/luis-paz-ares/), [Martin Reck](https://onco.cc/people/martin-reck/), [Martin Schuler](https://onco.cc/people/martin-schuler/), [Matthew D. Hellmann](https://onco.cc/people/matthew-hellmann/), [Matthew Meyerson](https://onco.cc/people/matthew-meyerson/), [Matthias Guckenberger](https://onco.cc/people/matthias-guckenberger/), [Maximilian Diehn](https://onco.cc/people/maximilian-diehn/), [Michael Boyer](https://onco.cc/people/michael-boyer/), [Miriam Merad](https://onco.cc/people/miriam-merad/), [Myung-Ju Ahn](https://onco.cc/people/ahn-myung-ju/), [Natasha B. Leighl](https://onco.cc/people/natasha-leighl/), [Nathan A. Pennell](https://onco.cc/people/nathan-pennell/), [Nei-Min Chu](https://onco.cc/people/nei-min-chu/), [Nikolaus Rajewsky](https://onco.cc/people/nikolaus-rajewsky/), [Nobuyuki Yamamoto](https://onco.cc/people/nobuyuki-yamamoto/), [Óscar Gerardo Arrieta Rodríguez](https://onco.cc/people/oscar-arrieta-rodriguez/), [Pasi A. Jänne](https://onco.cc/people/pasi-janne/), [Patrick M. Forde](https://onco.cc/people/patrick-forde/), [Paul K. Paik](https://onco.cc/people/paul-paik/), [Pilar Garrido](https://onco.cc/people/pilar-garrido/), [Primo N. Lara Jr.](https://onco.cc/people/primo-lara/), [Qing Zhou](https://onco.cc/people/qing-zhou/), [Ramaswamy Govindan](https://onco.cc/people/ramaswamy-govindan/), [Regina Barzilay](https://onco.cc/people/regina-barzilay/), [Reinhard Büttner](https://onco.cc/people/reinhard-buettner/), [Robert C. Doebele](https://onco.cc/people/robert-doebele/), [Robert D. Timmerman](https://onco.cc/people/robert-timmerman/), [Rolf A. Stahel](https://onco.cc/people/rolf-stahel/), [Roman Thomas](https://onco.cc/people/roman-thomas/), [Roy S. Herbst](https://onco.cc/people/roy-herbst/), [Scott J. Antonia](https://onco.cc/people/scott-antonia/), [Se-Hoon Lee](https://onco.cc/people/lee-se-hoon/), [Shun Lu](https://onco.cc/people/lu-shun/), [Sir Richard Peto](https://onco.cc/people/richard-peto/), [Solange Peters](https://onco.cc/people/solange-peters/), [Stephen B. Baylin](https://onco.cc/people/stephen-baylin/), [Suresh S. Ramalingam](https://onco.cc/people/suresh-ramalingam/), [Suzanne L. Topalian](https://onco.cc/people/suzanne-topalian/), [Takashi Kohno](https://onco.cc/people/kohno-takashi/), [Tasuku Honjo](https://onco.cc/people/tasuku-honjo/), [Thomas J. Lynch Jr.](https://onco.cc/people/thomas-lynch/), [Timothy A. Chan](https://onco.cc/people/timothy-chan/), [Tina Cascone](https://onco.cc/people/tina-cascone/), [Tony S. K. Mok](https://onco.cc/people/tony-mok/), [Valerie W. Rusch](https://onco.cc/people/valerie-rusch/), [Vanita Noronha](https://onco.cc/people/noronha-vanita/), [Weimin Li](https://onco.cc/people/li-weimin/), [Wen-Zhao Zhong](https://onco.cc/people/wen-zhao-zhong/), [Wenfeng Fang](https://onco.cc/people/fang-wenfeng/), [Woong-Yang Park](https://onco.cc/people/park-woong-yang/), [Yi-Long Wu](https://onco.cc/people/wu-yi-long/), [You Lu](https://onco.cc/people/lu-you/), [Yuankai Shi](https://onco.cc/people/shi-yuankai/), [Yuichiro Ohe](https://onco.cc/people/ohe-yuichiro/)
- bottlenecks: [Acquired resistance to every therapy](https://onco.cc/bottlenecks/b-resistance/), [AI that is built but not validated or deployed](https://onco.cc/bottlenecks/b-ai-validation/), [Biomarkers are not validated or standardised](https://onco.cc/bottlenecks/b-biomarker-validation/), [Cachexia, toxicity and the limits of the patient](https://onco.cc/bottlenecks/b-cachexia-supportive/), [Dormant cells and minimal residual disease](https://onco.cc/bottlenecks/b-dormancy-mrd/), [Fragmented care and guideline gaps](https://onco.cc/bottlenecks/b-care-fragmentation/), [Funding follows fashion, not burden](https://onco.cc/bottlenecks/b-funding-allocation/), [Incentives reward me-too drugs and marginal gains](https://onco.cc/bottlenecks/b-incentive-misalignment/), [Knowledge reaches practice too slowly](https://onco.cc/bottlenecks/b-knowledge-diffusion/), [Metastasis is understood least and studied last](https://onco.cc/bottlenecks/b-metastasis-biology/), [Misinformation and unproven therapies](https://onco.cc/bottlenecks/b-misinformation/), [No one can predict who responds to immunotherapy](https://onco.cc/bottlenecks/b-immunotherapy-response/), [Older and multimorbid patients are excluded and undertreated](https://onco.cc/bottlenecks/b-aging-comorbidity/), [Overdiagnosis and false alarms](https://onco.cc/bottlenecks/b-overdiagnosis/), [Pain relief and palliative care are unavailable to most](https://onco.cc/bottlenecks/b-palliative/), [Prevention we already have is not deployed](https://onco.cc/bottlenecks/b-prevention-adoption/), [The brain: barrier and sanctuary](https://onco.cc/bottlenecks/b-brain-delivery/), [The hardest cancers are found late](https://onco.cc/bottlenecks/b-early-detection/), [The undruggable drivers](https://onco.cc/bottlenecks/b-undruggable-targets/), [Too many combinations to test](https://onco.cc/bottlenecks/b-combination-space/), [Trials do not represent the people who get cancer](https://onco.cc/bottlenecks/b-trial-diversity/), [Tumour heterogeneity and clonal evolution](https://onco.cc/bottlenecks/b-tumor-heterogeneity/), [Wrong doses](https://onco.cc/bottlenecks/b-dose-optimisation/)
- collections: [Australia's national cancer screening programs](https://onco.cc/collections/australia-cancer-screening-programs/), [LUNGevity Foundation (and GO2 for Lung Cancer)](https://onco.cc/collections/lungevity/), [NHS cancer screening programmes](https://onco.cc/collections/nhs-cancer-screening-programmes/)
- key papers: [Aaronson 1993: the EORTC QLQ-C30 quality of life questionnaire](https://onco.cc/key-papers/paper-aaronson-eortc-qlq-c30-jnci-1993/), [ADAURA: exploratory eight-year overall survival update for adjuvant osimertinib in resected EGFR-mutated stage IB to IIIA lung cancer](https://onco.cc/key-papers/paper-adaura-8-year-os-jto-2026/), [ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer](https://onco.cc/key-papers/paper-adaura-nejm-2020/), [Allemani 2018: CONCORD-3, global surveillance of cancer survival 2000 to 2014](https://onco.cc/key-papers/paper-allemani-concord-3-lancet-2018/), [ASCO 2021 guideline: how to recognise and manage the immune-related side effects of checkpoint inhibitors](https://onco.cc/key-papers/paper-asco-irae-guideline-jco-2021/), [Bray 2018: GLOBOCAN 2018, worldwide incidence and mortality for 36 cancers](https://onco.cc/key-papers/paper-bray-globocan-2018-cacancer-2018/), [Bray 2024: GLOBOCAN 2022, the world's cancer count for 36 cancers in 185 countries](https://onco.cc/key-papers/paper-bray-globocan-2022-cacancer-2024/), [Brigatinib in patients with crizotinib-refractory ALK-positive non-small-cell lung cancer: a randomized, multicenter phase II trial (ALTA)](https://onco.cc/key-papers/paper-alta-jco-2017/), [Cancer Statistics, 2020: Report from National Cancer Registry Programme, India](https://onco.cc/key-papers/paper-mathur-ncrp-cancer-statistics-2020/), [CheckMate 017: nivolumab beats docetaxel in squamous lung cancer after chemotherapy](https://onco.cc/key-papers/paper-checkmate-017-nejm-2015/), [CheckMate 057: nivolumab beats docetaxel after chemotherapy in non-squamous lung cancer](https://onco.cc/key-papers/paper-checkmate-057-nejm-2015/), [CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery](https://onco.cc/key-papers/paper-checkmate-816-nejm-2022/), [Chen 2016: Cancer statistics in China, 2015](https://onco.cc/key-papers/paper-chen-cancer-statistics-china-2015-cacancer-2016/), [CodeBreaK 200: sotorasib versus docetaxel in KRAS G12C-mutated lung cancer, a modest win for the first KRAS drug](https://onco.cc/key-papers/paper-codebreak-200-lancet-2023/), [CROWN: lorlatinib versus crizotinib as first treatment for ALK-positive lung cancer](https://onco.cc/key-papers/paper-crown-nejm-2020/), [Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial](https://onco.cc/key-papers/paper-archer-1050-lancet-oncol-2017/), [Doll and Hill 1950: the case-control study that tied smoking to lung cancer](https://onco.cc/key-papers/paper-doll-hill-smoking-lung-cancer-bmj-1950/), [Fifty years of the British Doctors Study: smokers lose ten years of life, quitting gives most of it back](https://onco.cc/key-papers/paper-doll-peto-50-year-doctors-bmj-2004/), [First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study](https://onco.cc/key-papers/paper-ascend-4-lancet-2017/), [Fitzmaurice 2017: the Global Burden of Disease estimate of cancer in 2015](https://onco.cc/key-papers/paper-fitzmaurice-gbd-cancer-2015-jamaoncol-2017/), [FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer](https://onco.cc/key-papers/paper-flaura-nejm-2018/), [FLAURA2: long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced lung cancer](https://onco.cc/key-papers/paper-flaura2-long-term-safety-lung-cancer-2026/), [HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer](https://onco.cc/key-papers/paper-harmoni-2-lancet-2025/), [Hollstein 1991: p53 mutations in human cancers](https://onco.cc/key-papers/paper-hollstein-p53-mutations-science-1991/), [Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations](https://onco.cc/key-papers/paper-archer-1050-os-jco-2018/), [Jemal 2011: Global cancer statistics (GLOBOCAN 2008)](https://onco.cc/key-papers/paper-jemal-global-cancer-statistics-2011-cacancer/), [KEYNOTE-001 (Garon 2015): pembrolizumab in non-small-cell lung cancer and the 50% PD-L1 cut-off](https://onco.cc/key-papers/paper-keynote-001-pembrolizumab-nsclc-nejm-2015/), [KEYNOTE-010 (Herbst 2016): pembrolizumab versus docetaxel in previously treated PD-L1-positive lung cancer](https://onco.cc/key-papers/paper-keynote-010-lancet-2016/), [KEYNOTE-024: pembrolizumab alone beats chemotherapy in PD-L1-high lung cancer](https://onco.cc/key-papers/paper-keynote-024-nejm-2016/), [KEYNOTE-189: pembrolizumab plus chemotherapy as first treatment for non-squamous lung cancer without a driver mutation](https://onco.cc/key-papers/paper-keynote-189-nejm-2018/), [KRYSTAL-12 plain language summary: adagrasib for non-small-cell lung cancer with KRAS G12C mutations](https://onco.cc/key-papers/paper-krystal-12-plain-language-summary-future-oncol-2026/), [MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer](https://onco.cc/key-papers/paper-mariposa-nejm-2024/), [NELSON: volume-based CT screening reduces lung cancer deaths with fewer false alarms](https://onco.cc/key-papers/paper-nelson-nejm-2020/), [NLST: yearly low-dose CT scans cut lung cancer deaths in heavy smokers](https://onco.cc/key-papers/paper-nlst-nejm-2011/), [Ostrem and Shokat: the hidden pocket that made KRAS G12C druggable](https://onco.cc/key-papers/paper-ostrem-kras-g12c-nature-2013/), [PACIFIC: a year of durvalumab after chemoradiotherapy for stage III lung cancer](https://onco.cc/key-papers/paper-pacific-nejm-2017/), [Parkin 2005: Global cancer statistics, 2002](https://onco.cc/key-papers/paper-parkin-global-cancer-statistics-2002-cacancer-2005/), [Rizvi 2015: the mutational landscape determines who responds to PD-1 blockade in lung cancer](https://onco.cc/key-papers/paper-rizvi-mutational-landscape-pd1-science-2015/), [Siegel 2022: Cancer statistics, 2022](https://onco.cc/key-papers/paper-siegel-cancer-statistics-2022-cacancer-2022/), [Sung 2021: GLOBOCAN 2020, the year breast cancer overtook lung cancer as the most diagnosed cancer](https://onco.cc/key-papers/paper-sung-globocan-2020-cacancer-2021/), [Temel: early palliative care alongside chemotherapy improved quality of life, mood and survival in lung cancer](https://onco.cc/key-papers/paper-temel-early-palliative-care-nejm-2010/), [Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer](https://onco.cc/key-papers/paper-topalian-anti-pd1-nejm-2012/), [Torre 2015: Global cancer statistics, 2012](https://onco.cc/key-papers/paper-torre-global-cancer-statistics-2012-cacancer-2015/), [TRACERx 421: the full-cohort picture of how lung cancer evolves and which subclones drive relapse](https://onco.cc/key-papers/paper-tracerx-evolution-nature-2023/), [TRACERx first 100: tracking how lung cancers evolve, and how chromosomal chaos predicts relapse](https://onco.cc/key-papers/paper-tracerx-100-nejm-2017/), [Use of alternative medicine for cancer and its impact on survival](https://onco.cc/key-papers/paper-johnson-alternative-medicine-jnci-2018/)
- biomarkers: [ALK fusion (ALK-positive)](https://onco.cc/biomarkers/alk-fusion/), [BRAF class II and class III mutations (non-V600)](https://onco.cc/biomarkers/braf-class-ii-iii/), [BRAF V600E (and V600K)](https://onco.cc/biomarkers/braf-v600e/), [c-Met protein overexpression (IHC 3+ in >= 50% of tumour cells)](https://onco.cc/biomarkers/met-overexpression/), [CEACAM5 expression](https://onco.cc/biomarkers/ceacam5-expression/), [ctDNA MRD positivity (molecular residual disease after curative treatment)](https://onco.cc/biomarkers/ctdna-mrd-positive/), [EGFR exon 19 deletion](https://onco.cc/biomarkers/egfr-exon-19-deletion/), [EGFR exon 20 insertion](https://onco.cc/biomarkers/egfr-exon-20-insertion/), [EGFR L858R](https://onco.cc/biomarkers/egfr-l858r/), [EGFR T790M](https://onco.cc/biomarkers/egfr-t790m/), [HER2 (ERBB2) activating mutation](https://onco.cc/biomarkers/her2-mutation/), [HER3 expression](https://onco.cc/biomarkers/her3-expression/), [KRAS G12C](https://onco.cc/biomarkers/kras-g12c/), [KRAS G12D (and other non-G12C KRAS mutations)](https://onco.cc/biomarkers/kras-g12d/), [MET amplification (gene copy number)](https://onco.cc/biomarkers/met-amplification-readout/), [MET exon 14 skipping mutation](https://onco.cc/biomarkers/met-ex14/), [NTRK1/2/3 gene fusion](https://onco.cc/biomarkers/ntrk-fusion/), [PD-L1 IC score (immune-cell score, SP142)](https://onco.cc/biomarkers/pd-l1-ic-score/), [PD-L1 TC score (tumour-cell score, SP263 and 28-8)](https://onco.cc/biomarkers/pd-l1-tc-score/), [PD-L1 TPS (tumour proportion score)](https://onco.cc/biomarkers/pd-l1-tps/), [RET fusion and RET mutation](https://onco.cc/biomarkers/ret-fusion/), [ROS1 fusion (ROS1-positive)](https://onco.cc/biomarkers/ros1-fusion/), [TMB-high (tumour mutational burden >= 10 mutations per megabase)](https://onco.cc/biomarkers/tmb-high/), [TROP2 expression](https://onco.cc/biomarkers/trop2-expression/)

---
JSON: https://onco.cc/api/v1/entities/nsclc.json